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Abstract
Tumor exosomes educate selected host tissues toward a prometastatic phenotype. We demonstrated this for exo-
somes of the metastatic rat adenocarcinoma BSp73ASML (ASML), which modulate draining lymph nodes and lung
tissue to support settlement of poorly metastatic BSp73ASML-CD44v4-v7 knockdown (ASML-CD44vkd) cells. Now,
we profiled mRNA and microRNA (miRNA) of ASMLwt and ASML-CD44vkd exosomes to define the pathway(s),
whereby exosomes prepare the premetastatic niche. ASML exosomes, recovered in draining lymph nodes after
subcutaneous injection, preferentially are taken up by lymph node stroma cells (LnStr) and lung fibroblasts (LuFb) that
were chosen as exosome targets. ASMLwt and ASML-CD44vkd exosomes contain a restricted mRNA and miRNA
repertoire that differs significantly between the two lines and exosomes thereof due to CD44v6 influencing gene
and miRNA transcription/posttranscriptional regulation. Exosomal mRNA and miRNA are recovered in target cells,
where transferred miRNA significantly affected mRNA translation. Besides others, this was exemplified for abundant
ASMLwt-exosomalmiR-494 andmiR-542-3p, which target cadherin-17 (cdh17). Concomitantly, matrix metalloproteinase
transcription, accompanying cdh17 down-regulation, was upregulated in LnStr transfected with miR-494 or miR-542-3p
or co-cultured with tumor exosomes. Thus, tumor exosomes target non-transformed cells in premetastatic organs
and modulate premetastatic organ cells predominantly through transferred miRNA, where miRNA from a metastasiz-
ing tumor prepares premetastatic organ stroma cells for tumor cell hosting. Fitting the demands of metastasizing
tumor cells, transferred exosomal miRNA mostly affected proteases, adhesion molecules, chemokine ligands, cell
cycle– and angiogenesis-promoting genes, and genes engaged in oxidative stress response. The demonstration of
function-competent exosomal miRNA in host target cells encourages exploiting exosomes as a therapeutic gene
delivery system.
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Introduction
Metastasis formation accounts for the majority of cancer-induced
deaths, where a given tumor type preferentially seeds in selected
organs [1,2]. Premetastatic niche preparation supports the seed and
soil hypothesis, as tumors prepare only defined organs for metastasiz-
ing cell settlement in advance of arrival [3–5]. Our suggestion that
tumor-derived exosomes rather than individual molecules play an
important role [6] was confirmed by several groups [7–16]. Exosomal
microRNA (miRNA) in serum is also discussed as a potential marker
for tumor diagnosis [17,18].
Exosomes, small vesicles delivered by many cells and abundantly
by tumor cells [19], derive from early endosomes, which fuse to multi-
vesicular bodies (MVBs), from where individual vesicles (exosomes) are
released in the extracellular space [20–23]. Accordingly, exosomes are
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rich in proteins located in internalization-prone membrane domains
and molecules engaged in fission, scission, and vesicular transport
[14,22,24,25]. Exosomes also harbor selected mRNA and miRNA [26].
mRNA recruitment may be guided by a zip code in the 3′ untranslated
region (3′UTR) [27]; miRNA recruitment is facilitated by physical and
functional coupling of RNA-induced silencing complexes to components
of the sorting complex, where GW182 containing GW bodies, sorted
into MVB, promotes continuous assembly/disassembly of membrane-
associated miRNA-loaded RNA-induced silencing complex [28,29].
Exosome binding and uptake by target cells are also selective processes
that involve various endocytic pathways and proteins from exosome
donor and target cells [30,31], where exosomal tetraspanin complexes
bind to selected ligands, which are also located in internalization-prone
microdomains [32,33]. Exosomal proteins, mRNA, and miRNA are
functionally active [22,34,35] and exosome binding/uptake can se-
verely alter target cells, as demonstrated for T cell activation, immuno-
suppression, and conversion to a malignant phenotype [14,36–38].
We showed for the metastasizing rat pancreatic adenocarcinoma
BSp73ASML (ASML) [39] that exosomes contribute to premetastatic
niche preparation. ASML cells highly express CD44 variant isoforms
v4–v7 (CD44v) [6], where CD44v6 particularly promotes the meta-
static phenotype [40]. First evidence for CD44v as a metastasis-promoting
molecule deriving from metastasis formation of CD44v transfected
non-metastasizing BSp73AS cells [41] was confirmed in numerous
studies in human and animal models [ref. in 42]. The central role of
CD44v in metastasis formation was confirmed by a knockdown of
CD44v4-v7 (ASML-CD44vkd) in ASML cells that poorly metastasize
[43]. As the metastatic process essentially depends on the cross talk
between tumor cells and the host and exosomes being suggested to
be the most important intracellular communicators, we speculated that
ASMLwt exosomes might account for the metastatic spread. Control-
ling this hypothesis was facilitated by the peculiarity of ASML cells not
to grow locally after subcutaneous injection and to form metastases
selectively in lymph nodes and lung [39]. Thus, if ASML exosomes
contribute to premetastatic organ preparation, ASML-CD44vkd cells
that also do not grow locally should regain metastatic capacity after pre-
paring the host with ASMLwt exosomes. Indeed, poorly metastasizing
ASML-CD44vkd cells regain metastatic capacity, when rats are pre-
treated with conditioned medium (CM) of ASMLwt cells. The essential
contribution of exosomes was supported by the finding that exosome-
depleted CM (CM−exo) exerted no metastasis-promoting effect. Fur-
thermore, compared to ASMLwt exosomes, ASML-CD44vkd exosomes
exerted a weaker effect [6]. To obtain hints toward the weaker effect of
ASML-CD44vkd versus ASMLwt exosomes, we explored the impact of
metastasis-promoting CD44v6 on the exosomal mRNA, miRNA, and
protein profiles and progressed toward elucidating how tumor exo-
somes modulate premetastatic organs using lymph node stroma cells
(LnStr) and lung fibroblasts (LuFb) as targets.
Materials and Methods
Cell Lines
ASMLwt cells derive from the metastasizing variant of a spontane-
ously arisen rat pancreatic adenocarcinoma in the BDX rat strain.
Subcutaneously implanted ASML cells do not grow locally and me-
tastasize exclusively to lymph nodes and lung [39]. ASML-CD44vkd
cells do not also grow locally. They metastasize with a strong delay to
draining lymph nodes and do not settle in the lung [43]. A rat aortic
endothelial cell line (EC) and a fibroblast line (LuFb) derived from the
lung of BDX rats spontaneously immortalized. These lines as well as
human embryo renal cortical cells (HEK293) and LnStr (B12) [44] were
maintained in RPMI 1640/10% fetal calf serum, supplemented for
ASML-CD44vkd cells with 750 μg/ml G418.
Antibodies
For antibodies, see Table W1.
Exosome Preparation
Cells were cultured (48 hours) in serum-free medium. Cleared
supernatants (2 × 10 minutes, 500g; 1 × 20 minutes, 2000g; 1 ×
30 minutes, 10,000g) were centrifuged (90 minutes, 100,000g) and
washed [phosphate-buffered saline (PBS), 90 minutes, 100,000g].
The supernatant after the last centrifugation was collected as CM−exo.
It was concentrated and, after protein determination, adjusted to
200 μg/25 μl for intrafootpad (ifp) injection. The pellet was resus-
pended (10 ml of PBS), layered on 10 ml of 40% sucrose, and centri-
fuged (90 minutes, 100,000g). The top layer was removed; the sucrose
layer was diluted with PBS and centrifuged (90 minutes, 100,000g).
Where indicated, exosomes were rhodamine–N-(lissamine rhodamine
B sulfonyl ) phosphatidyl ethanolamine (DHPE)– or SP-Dio18(3)–
labeled (Invitrogen, Karlsruhe, Germany). Exosomes were directly labeled
(30 minutes, 4°C) before sucrose gradient centrifugation and washed
twice (90 minutes, 100,000g). Relative fluorescence intensity was ad-
justed to rhodamine-DHPE or SP-Dio18(3) standards.
mRNA and miRNA
After RNAse treatment, exosomal and cellular mRNA/miRNA
were extracted using TRI reagent according to recommendation
(Sigma, Munich, Germany).
Microarray mRNA Analysis
Expression levels of 22,523 rat transcripts of two independent
preparations of ASMLwt and ASML-CD44vkd exosomes and cells
and of untreated and ASMLwt- or ASML-CD44vkd exosome–treated
LnStr cells were analyzed in duplicates or triplicates using Ilumina
and SurePrintG3Rat-GE-8x60K microarray. Analyses, normalization,
and statistics (Chipster analysis and Agilent annotation) were per-
formed at the Core Facility, German Cancer Research Center. Cellular
and exosomal samples were normalized independently. Transcripts with
at least double signal intensity over background, bead standard error
differences > 12, and P value < .05 were included (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE34739). RNA was analyzed
according to function clustering (http://www.pantherdb.org).
Microarray miRNA Analysis
miRNA analysis of ASMLwt and ASML-CD44vkd exosomes and cells
(Core Facility, European Molecular Biology Laboratories, Heidelberg,
Germany) used the miRCURY LNA microRNA ver11.0-hsa,mmu,
rno or the Agilent microRNA microarray evaluating quadruplicates of
two independent preparation (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE34739).Mean values of normalized data (Agilent Feature
Extraction Software) were compared. Differentially regulated miRNA
were defined as those with more than two-fold changes in signal strength.
The miRNA database (http://www.microrna.org) and the target scan
database (http://www.targetscan.org) were used to predict potential
miRNA targets and for correlating downregulated mRNA in exosome-
treated LnStr with exosomal miRNA.
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Reverse Transcription and Quantitative Reverse
Transcription–Polymerase Chain Reaction
Reverse transcription (RT) reactions contained RNA samples includ-
ing purified total RNA, cell lysate, or heat-treated cells, 50 nM stem loop
reverse transcriptase primer (Applied Biosystems,Darmstadt, Germany),
1× reverse transcriptase buffer (Applied Biosystems), 0.25 mM each
of deoxyribonucleoside triphosphates (dNTPs), 3.33 U/μl Multi-
Scribe reverse transcriptase (Applied Biosystems), and 0.25 U/μl RNase
inhibitor (Applied Biosystems). The 7.5-μl reactions were incubated
in an Applied Biosystems 9700 Thermocycler in a 96- or 384-well
plate for 30 minutes at 16°C, 30 minutes at 42°C, and 5 minutes at
85°C and then held at 4°C. All reverse transcriptase reactions, includ-
ing no template controls and reverse transcriptase minus controls, were
run in duplicate.
Real-time polymerase chain reaction (PCR) was performed using a
standard TaqMan PCR kit protocol on an Applied Biosystems 7900HT
Sequence Detection System (Applied Biosystems). The 10-μl PCR in-
cluded 0.67 μl of reverse transcriptase product, 1× TaqMan Universal
PCRMaster Mix (Applied Biosystems), 0.2 μMTaqMan probe, 1.5 μM
forward primer, and 0.7 μM reverse primer. The reactions were incu-
bated in a 384-well plate at 95°C for 10 minutes, followed by 40 cycles
of 95°C for 15 seconds and 60°C for 1 minute. All reactions were
run in triplicate. Glyceraldehyde phosphate dehydrogenase (GAPDH)
served as internal control for mRNA and 4.5SRNA was used as internal
control for miRNA. The threshold cycle (CT) is defined as the frac-
tional cycle number at which the fluorescence passes the fixed thresh-
old. TaqMan CT values were converted into absolute copy numbers
using a standard curve from synthetic lin-4 miRNA. Statistical analysis
was done by the ΔCT method [
ΔCT = CT test gene − CT endogenous
control; ΔΔCT =
ΔCT sample −
ΔCT calibrator (untreated LnStr)], where
relative quantification/fold change compared to the calibrator = 2−ΔΔCT.
miRNA Transfection
LnStr and HEK293 cells, seeded in antibiotic-free medium (24
hours), were transfected with 20 nM [quantitative RT-PCR (qRT-
PCR)] or 10 nM (luciferase reporter assay) miRNA mimic (Qiagen,
Hilden, Germany) using Lipofectamine 2000. After 48 hours,
mRNA regulation was evaluated by qRT-PCR and/or was verified
by flow cytometry (protein level) or used for luciferase reporter assay.
3′UTR Reporter Assay
miRNAs that could bind in the 3′UTR of MAL and cadherin-17
(cdh17) mRNAs were searched according to http://www.microrna.
org. Those showing a good mirSVR score (lower than −0.1) and de-
tected in exosomes were selected. The 3′UTR regions were cloned by
PCR from genomic LnStr DNA (primers: Table W2). PCR products
were cloned into the dual-luciferase pmiRGlo vector, downstream of
firefly luciferase using Pme1 and Xba1 restriction sites. After ligation
and bacterial transformation, positive clones (sequenced) were used
for HEK293 transfection. HEK293 cells were transfected with
cloned miRNA binding sites for miR-300-5p or of the 3′UTRs of
MAL and cdh17 using HiPerFect for reverse transfection in 96-well
plates. Briefly, miRNA mimics (10 nM; Qiagen) without or with
80 ng of the reporter plasmid was spotted in a well of 96-well flat-
bottom plates. Thereafter, HiPerFect reagent (1 μl, diluted in 25 μl
of serum-free medium) was added to the miRNA/DNA and mixed
by pipetting. After an incubation time of 10 minutes, 4 × 105 cells in
Iscoves/10% fetal calf serum were added. The cells were maintained
under normal growth condition for 48 hours. The Dual-Luciferase
Reporter Assay Kit (Promega, Mannheim, Germany) was performed
following the manufacturer’s instruction. Cells were lysed in 20 μl of
Dual-Glo reagent (15 minutes, reverse transcriptase); the lysate was
added to 100 μl of the same reagent in a white 96-well plate (Promega),
and the firefly luciferase was measured using FLUOstar OPTIMA
luminometer (BMG LABTECH, Offenburg, Germany), followed by
measurement of Renilla luciferase, which was used for normalization
of transfection efficiency.
In Vitro Translation
Exosomal RNA (10 μg) in water was mixed with 1.25 μl of 20×
translation mix (Retic Lysate IVT Kit), 1 μl of 35S-methionine, and
17 μl of Retic lysate, adjusted to 25 μl with nuclease-free water. After
vortexing and centrifugation, the reaction mix at the bottom of the
tube was incubated for 90 minutes in a 30°C water bath and for
10 minutes with 2.5 μl of RNaseA; 10 μl of the complete reaction
was mixed with an equal volume of 2× sodium dodecyl sulfate sam-
ple buffer and incubated for 5 minutes at 95°C. After centrifugation,
samples were collected from the bottom and allowed to cool to room
temperature. Samples were loaded on a 12% sodium dodecyl sulfate–
gel. After electrophoresis, proteins were fixed (45% methanol and
10% acetic acid, 5 minutes, gentle agitation) and dried. Dried gels
were exposed at −70°C for 48 hours to X-ray films using an intensi-
fying screen and photographed.
Flow Cytometry
Flow cytometry for cells followed routine procedures. Where in-
dicated, cells were fixed and permeabilized and/or stripped (two
washes in PBS/HCl, pH 2.5). Exosomes (10–15 μg) were incubated
with 1 μl of aldehyde-sulfate latex beads (4 μm) (Invitrogen) in PBS/
1% BSA (90 minutes, 20°C, shaking). After centrifugation, free
binding sites on the beads were blocked by incubation with 100 mM
glycine in PBS (1 hour). After washing two times with PBS/1% BSA,
exosome-coated beads (corresponding to 1 μl beads/well) are distrib-
uted in 96-well plates. Staining with primary and secondary dye-
labeled antibodies follows the protocol for cell staining. For analyzing
exosome uptake, cells were incubated with DHPE-labeled exosomes,
washed, and stripped. Samples were analyzed in a FACSCalibur using
the CellQuest program.
Zymography
CM of LnStr (1 × 106), starved for 24 hours, was centrifuged
(15 minutes, 15,000g). Aliquots of supernatant were incubated with
Laemmli buffer (15 minutes, 37°C) and separated in a 10% acrylam-
ide gel containing 1 mg/ml gelatin. After washing (2.5% Triton), gels
were incubated in developing buffer (37°C, 48 hours) and stained
with Coomassie Blue.
In Vivo Assays
Rats (three per group) receiving 200 μg of SP-Dio18(3)–labeled
exosomes in 25 μl of RPMI 1640, ifp, were sacrificed after 24 to
72 hours. Rats (three per group) receiving exosomes in RPMI
1640 or 20-fold concentrated CM−exo of ASMLwt or ASML-
CD44vkd cells, ifp, were sacrificed after 48 hours. Popliteal lymph
nodes were excised and dispersed to evaluate exosome uptake by flow
cytometry. The experiment was government-approved (Baden-
Wuerttemberg, Germany).
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Statistical Analysis
All in vitro assays were run in triplicates and repeated at least three
times. P values < .05 (two-tailed Student’s t test, analysis of variance)
were considered significant. The mRNA and miRNA microarray
analyses were performed with two independent samples, each run in
duplicate or triplicate (mRNA) or quadruplicate (miRNA) and con-
tained 60 (mRNA) or >30 (miRNA) negative controls. As the duplicate/
triplicate (mRNA) and quadruplicate (miRNA) samples frequently
revealed P values < .05 with as low a variation in the signal strength
as 1.2, mean values of the duplicates/quadruplicates of the two inde-
pendent performed microarray analyses are presented throughout,
where it should be noted that in the absolute ranking the individual
mRNA/miRNA were very close and the few samples where this has
not been the case were excluded. Nonetheless, as the total signal
strength between the two microarrays differed, P values < .05 were rare
and are only occasionally included. Instead, we indicate more than
two-fold differences (which is five times the level to reach significant
P values within the individual microarray analysis).
Results
ASML cells, not forming a local tumor, metastasize through the lym-
phatics to the lung [39], indicating an essential requirement of lymph
node or lung environment for growth. This feature makes ASML
cells ideal candidates for defining a tumor’s impact on premetastatic
niche preparation. In a previous work indicating that exosomes are
essential [6], we here characterized ASMLwt exosomes and defined their
impact on LnStr and LuFb. The comparison with ASML-CD44vkd
exosomes aimed for hints toward their lower efficacy.
In Vivo and In Vitro Exosome Binding and Uptake
As a prerequisite for in vivo activity, we controlled that tumor exo-
somes reach the premetastatic organ from the distant site of the pri-
mary tumor. Ifp-injected ASMLwt exosomes were recovered in the
popliteal node after 24 to 72 hours. ASMLwt exosome and, far more
pronounced, ASML-CD44vkd exosome recovery was significantly in-
creased, when supported by ASMLwt-CM−exo. The ASML-CD44vkd-
CM−exo hardly supported exosome traffic toward the popliteal node
(Figure 1, A–C ).
ASML exosomes are taken up by leukocytes [45] and stroma cells.
As ASML cells metastasize exclusively through the lymphatic system,
we chose LnStr and LuFb as targets to explore in vitro the impact of
tumor exosomes. ASMLwt exosomes bind more rapidly than ASML-
CD44vkd exosomes to LnStr and LuFb. Both exosomes bind less effi-
ciently to ECs, included as control (Figure 1,D andE). Bound exosomes
are taken up by their targets, as seen in the sagittal sections of exosome-
treated LnStr and LuFb (Figure 1E) and confirmed by exposing LnStr
and LuFb to two acid washes (pH 2.5; stripping), which remove bound
without affecting integrated exosomes. ASMLwt exosome uptake pro-
ceeds more rapidly than ASML-CD44vkd exosome uptake (Figure 1,
F and G).
Thus, ASML exosomes reach the premetastatic organ in vivo and
are in vitro taken up by LnStr and LuFb. The CD44vkd has some, not
yet, explored impact on the efficacy of exosome binding and uptake.
ASML Exosomal mRNA and miRNA
Having demonstrated that ASMLwt and ASML-CD44vkd exo-
somes are taken up by host stroma cells, though with distinct efficacy,
we focused on the potential contribution of CD44v to protein, mRNA,
and miRNA recruitment into exosomes, where mRNA and miRNA are
claimed to be selectively recruited into MVB/exosomes [20–23,26].
The RatRef-12 expression BeadChip array (23,365 transcripts) re-
vealed <1500 mRNAs in ASMLwt and ASML-CD44vkd exosomes
(Table W3) but >8000 mRNAs in ASML cells (Table W4), indicating
a restricted mRNA uptake by exosomes. To strengthen the assumption,
we compared the relative abundance of exosomal versus cellular mRNA.
Although the overall distribution of function-assigned groups of
mRNA was similar in ASMLwt and ASML-CD44vkd exosomes and
cells and also LnStr (data not shown), the relative abundance of exo-
somal versus cellular mRNA differed. From 116 mRNAs highly recov-
ered in ASMLwt exosomes, the relative recovery of >90 mRNAs differed
more than two-fold in ASMLwt cells. Similar findings accounted for the
comparison of ASML-CD44vkd exosomes versus cells (Table W5 and
Figure W1). An elegant study by Eldh et al. [46] demonstrated that the
mRNA isolation kit that was used provides a poor yield of exosomal
mRNA. Nonetheless, several mRNAs were clearly enriched in exo-
somes. However, according to the above-mentioned study, we cannot
exclude that an even higher number of mRNA is enriched in exosomes.
As some mRNAs were enriched in ASMLwt as well as ASML-CD44vkd
exosomes, we next asked whether CD44v has an impact on mRNA
recruitment into MVB. To obtain a hint, we evaluated the mRNA
in ASMLwt cells versus ASML-CD44vkd cells and compared these dif-
ferences in cellular mRNAwith those seen in exosomes. Should CD44v
contribute to mRNA recruitment into exosomes, one would expect
a significantly higher number of distinctly recovered mRNA in
ASMLwt exosomes than in cells. This has not been the case. Taking
the 50 mRNAs with the highest signal intensity, two exosomal versus
three cellular mRNA differed more than two-fold depending on
CD44v (Figure 2, A and B). Taking 2390 defined mRNAs in ASMLwt
exosomes with a signal strength of >1000, only 74 (3.1%) differed
more than two-fold in ASML-CD44vkd exosomes. Furthermore, when
analyzing the cellular-to-exosomal mRNA ratio for 14 mRNAs (signal
strength > 400), where the exosomal ASMLwt mRNA was at least
two-fold higher than the ASML-CD44vkd mRNA, no correlation
to a higher ASMLwt than ASML-CD44vkd cellular mRNA ratio was
detected. Accordingly, no inverse correlation of the cellular mRNA
was detected for ASML-CD44vkd exosomes containing a higher
mRNA level than ASMLwt exosomes (Figure W2).
However, CD44v could still contribute to the protein composition
of exosomes. To answer this question, we selected cellular mRNA of
proteins abundantly expressed in exosomes (http://www.exocarta.
org). From 164 selected proteins with a cellular mRNA signal >
1000 in ASMLwt cells, 25% showed a more than two-fold change
in signal strength in ASML-CD44vkd cells, which is shown for the
50 mRNAs with the highest signals (Figure 2C ) and as scatter for
the first 100 mRNAs (Figure W3). The impact of CD44v on these
mRNAs is reflected at the cellular and exosomal protein levels dem-
onstrated by flow cytometry for CD24 and claudin-4 that expression
is reduced in ASML-CD44vkd cells and exosomes, whereas caveolin-1
and CD81 expression are higher in ASML-CD44vkd than in ASMLwt
cells and exosomes (Figure 2D).
A rather low number (89–98) of miRNA were recovered in
ASMLwt and ASML-CD44vkd exosomes and cells (Table W6 and
Figure W4: most abundant miRNA). With a >1000 signal strength
cutoff, 21 cellular and 50 exosomal miRNAs differed more than two-
fold between ASMLwt and ASML-CD44vkd cells/exosomes (Fig-
ure W5). The distinct recovery in ASMLwt versus ASML-CD44vkd cells
indicates a direct or indirect contribution of CD44v6 to miRNA
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transcription or posttranscriptional regulation. Should CD44v, in
addition, actively contribute to miRNA recruitment into MVB/
exosomes, one would expect that the ratio of cellular to exosomal
miRNA differs in dependence on CD44v expression. This has not been
the case. With very few exceptions, the ratio of ASMLwt to ASML-
CD44vkd miRNA in cells did not differ significantly from that in
exosomes and only one miRNA (miR-30e) was opposingly recruited
into ASMLwt versus ASML-CD44vkd exosomes (Figure 3).
Taken together, exosomes collect a limited number of mRNA and
miRNA. The abundant differences in the mRNA of ASMLwt versus
ASML-CD44vkd cells argue for CD44v or associated molecules being
engaged in gene transcription/regulation. This includes genes whose
protein products are enriched in exosomes [6,45, Figure W3, and
unpublished findings]. However, differences at the cellular mRNA
level between ASMLwt and ASML-CD44vkd cells are closely reflected
by differences in exosomes. Thus, CD44v seemingly does not actively
contribute to MVB formation and has, if at all, only a minor impact
on mRNA recruitment into MVB.
Having characterized ASMLwt and ASML-CD44vkd exosomal
mRNA and miRNA, we asked whether they have any impact on exo-
some targets, where we focused on the general principle rather than on
the differences between ASMLwt versus ASML-CD44vkd exosomes.
Figure 1. Exosome binding and uptake by non-transformed cells in vivo and in vitro. (A–C) Dye-labeled ASMLwt and ASML-CD44vkd
exosomes in RPMI 1640, ASMLwt, or ASML-CD44vkd-CM−exo were injected ifp. Rats were sacrificed after 24 to 72 hours; the injection
site and the popliteal node were excised and dispersed, and fluorescent exosome uptake was evaluated in single-cell suspensions by
flow cytometry counting 100,000 cells for each organ in triplicate. (A) Mean values ± SD (triplicates, three rats) of fluorescent cells;
significant differences between ASMLwt and ASML-CD44vkd exosomes: *. (B) Mean values ± SD (triplicates, three rats) of fluorescent
cells; significant differences in the presence of CM−exo: *, and between ASMLwt- and ASML-CD44vkd exosomes: s. (C) representative
example. (D–G) LuFb, LnStr, and EC were incubated with dye-labeled ASMLwt and ASML-CD44vkd exosomes (30 μg/ml) for the indicated
times. (D) After washing, the percent fluorescent cells (mean ± SD, triplicates) were evaluated by flow cytometry; significant differences
between the percentage of cells that bind/take up ASMLwt versus ASML-CD44vkd exosomes: *. (E) Representative example of exosome
uptake as evaluated by flow cytometry and confocal microscopy. Overlays of light field and red fluorescence including sagittal sections
are shown (scale bar, 5 μm). (F and G) After 1, 2, and 6 hours, bound exosomes were removed by two acid washes (stripping), evaluating
remaining fluorescence as above. (F) The percentage of stained cells (mean ± SD of triplicates); significant differences between the
percentage of cells that bound/took up versus the percentage of cells that took up ASMLwt or ASML-CD44vkd exosomes: *. (G) Rep-
resentative examples are shown. Experiments in D to G were repeated at least three times revealing comparable results. ASMLwt and
ASML-CD44vkd exosomes reach the draining node; the efficacy can be improved by ASMLwt-CM. ASML exosomes bind more readily to
LuFb and LnStr than to EC. Binding and uptake of ASML-CD44vkd exosomes are less efficient and delayed compared to ASMLwt exo-
somes. It should be mentioned that the percentage of exosome uptake will be underestimated, as the signal strength of a single or few
exosomes will be below the detection limit.
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ASML Exosome mRNA and miRNA Are
Transferred into LnStr
We first reaffirmed for selected mRNA and miRNA the transfer into
target cells. For mRNA, C4.4A was chosen, as C4.4A is not detected in
LnStr. Instead, it was recovered after co-culture with exosomes
(Figure 4A). Though exosomal mRNA integrity was confirmed by
in vitro translation (data not shown), in vivo translation of C4.4A
was not detected. As revealed by double fluorescence analysis of LnStr
co-cultured with dye-labeled exosomes, upregulated expression/
translation of other more abundant exosomal mRNA, like CD24
and cyclin D1, was detected but was not restricted to LnStr that had
taken up ASMLwt exosomes (Figure 4B).
Figure 2. ASMLwt and ASML-CD44vkd cellular and exosomal mRNAs. (A and B) Examples of 50 defined mRNAs with the highest signal
strength in ASMLwt cells and exosomes and fold changes in ASML-CD44vkd cells and exosomes. (C) mRNA signals in ASMLwt cells and
fold change in ASML-CD44vkd cells for 50 proteins known to be highly recovered in exosomes. (A–C) Mean values were derived from
duplicates/triplicates in two independent microarray analyses, where it should be noted that in both arrays the absolute ranking of in-
dividual mRNA was very high, at least for those with a signal strength of >2000. However, whereas by calculating P values from the
duplicates/triplicates of the individual array 1.2-fold differences mostly were significant, the absolute signal strength varied between the
two arrays such that P values < .05 were mostly not reached. For these reasons, we indicate more than two-fold differences that are
generally accepted as non-random. (D) For selected mRNA, protein recovery was evaluated in ASMLwt and ASML-CD44vkd cells and
exosomes by flow cytometry. Representative examples and mean ± SD (triplicates) of staining intensity in ASMLwt and ASML-CD44vkd
cells and exosomes are shown. Significant differences between ASMLwt versus ASML-CD44vkd cells and exosomes: *. (D) The exper-
iment was repeated three times revealing comparable results. Exosomes contain a limited number of mRNA. However, more than two-
fold differences in ASMLwt versus ASML-CD44vkd exosomal mRNA are rare and not selectively recovered in exosomes, suggesting that
CD44v is unlikely to be directly involved in mRNA recruitment into MVB. Conversely, CD44v or associated molecules affect transcription
of several genes, including transcription of genes/expression of proteins, which are constitutive exosome components. Thereby, CD44v
contributes to the protein and mRNA profile of exosomes.
Figure 3. miRNA ratio in ASML cells versus exosomes. (A–D) The miRNAs (signal strength > 1000, mean of quadruplicates of two
microarray analyses) are depicted, where the ratio reveals a more than two-fold change in (A) ASMLwt and (B) ASML-CD44vkd cells
to exosomes and in (C) ASMLwt and (D) ASML-CD44vkd exosomes to cells; alike regulation in ASMLwt and ASML-CD44vkd cells versus
exosomes: *; opposing up-regulation or down-regulation: X. The miRNA profile of exosomes differs strikingly from that of cells, a con-
siderable number of cellular miRNA being not detected in exosomes and vice versa. Instead, there are minor differences in ASMLwt
versus ASML-CD44vkd cells and exosomes, indicating that CD44v might not be engaged in miRNA recruitment into MVB.
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miRNA transfer was confirmed for miR-300-5p and miR-296,
abundant in ASMLwt exosomes and found to be 4.5-fold and
17.3-fold increased in ASMLwt-exosome–treated compared to un-
treated LnStr. Notably, after co-culture with ASML-CD44vkd exo-
somes that express significantly less miR-300-5p, no significant
increase in miR-300-5p was seen in LnStr (Figure 4C ). Functional-
ity of the transferred exosomal miRNA was controlled by a reporter
assay with a dual-luciferase pmiRGlo vector with a binding site for
miR-300-5p downstream of the firefly luciferase gene. Luciferase
activity in HEK293 cells co-transfected with miR-300-5p mimic,
but also and importantly, when co-incubated with ASMLwt exo-
somes was significantly decreased. A similar effect was not observed
Figure 4. Recovery of exosomal mRNA and miRNA in target cells. (A) LnStr cells were co-cultured with ASMLwt exosomes. After 1 to
24 hours, mRNA was extracted, reverse transcribed, amplified with C4.4A-specific primers by RT-PCR, and separated by agarose gel.
(B) LnStr were co-cultured (6 hours) with DHPE-labeled ASMLwt exosomes and were stained with anti-C4.4A (C4.4), anti-CD24, and anti–
cyclin D1 after washing, fixation, and permeabilization. Flow cytometry of untreated and ASMLwt exosome–treated LnStr (overlay with
negative control and double fluorescence: DHPE-labeled exosomes and marker) is shown. (C) After 48 hours of co-culture, LnStr RNA
was extracted, reverse transcribed, and amplified using universal reverse primer and miR-specific forward primer with stem loop primers
for miR-296 and miR-300-5p. CT and relative quantification values (mean of three replicate samples with SD < 0.25, indicating reliability
according to the software program for ΔCT) in untreated versusASML
wt and ASML-CD44vkd exosome–treated LnStr are shown. (D) HEK293
cells were transfected with the dual-luciferase pmiRGlo vector containing a miR-300-5p binding site and were co-transfected with miR-300-
5p (10 nM) or co-cultured with ASMLwt or ASML-CD44vkd exosomes (20 μg). Firefly and, for normalization, Renilla luciferase activity was
evaluated after 48 hours in a FLUOstar OPTIMA luminometer. Relative luciferase activity (mean ± SD, triplicates) and P values for miR-300-
5p, ASMLwt and ASML-CD44vkd exosomes are shown. (C and D) Experiments were repeated three times revealing comparable results.
Exosomal mRNA and miRNA are transferred. In vivo mRNA translation was hardly detectable and endogenous transcription/translation
cannot be safely excluded. Transferred exosomal miRNA is active.
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after co-culture with low-level miR-300-5p expressing ASML-
CD44vkd exosomes (Figure 4D).
Taken together, exosomal mRNA and miRNA are transferred into
target cells. Exosomal miRNA is function-competent. Exosomal
mRNA becomes translated, but we could not unequivocally detect
the exosomal mRNA translation product, which might be due to
the low amount of exosomal mRNA.
The Impact of Exosomal mRNA on LnStr and LuFb
Having demonstrated exosomal mRNA and miRNA transfer,
we searched for altered mRNA recovery in LnStr after co-culture
with exosomes.
The signal strength of 38 mRNAs and 20 mRNAs with moderate
to high expression in LnStr increased more than two-fold after co-
culture with ASMLwt or ASML-CD44vkd exosomes, respectively
Figure 5. Impact of ASMLwt and ASML-CD44vkd exosomes on mRNA and protein expression in LnStr and LuFb. (A–D) LnStr and LuFb
were co-cultured for 48 hours with ASMLwt and ASML-CD44vkd exosomes. (A and B) Cells were harvested, washed, and lysed and
mRNA was extracted and analyzed (Ilumina and SurePrintG3Rat-GE-8x60K microarray). (A) Number of LnStr mRNA with a more than
two-fold change after co-culture with ASMLwt or ASML-CD44vkd exosomes. (B) mRNA in LnStr that are more than two-fold upregulated
after co-culture with exosomes and comparison of the relative mRNA amount in exosomes versus LnStr. (A and B) Mean values of
duplicates, respectively, triplicates, of two independent microarray analyses. (B) Significant differences between LnStr and LnStr co-
cultured with ASML exosomes: *. (C) Upregulated gene expression (selected examples) in LnStr co-cultured with exosomes was con-
firmed by qRT-PCR (mean of three replicate samples with SD < 0.25, indicating reliability according to the software program for ΔCT)
and (D) in LnStr and LuFb at the protein level by flow cytometry. The mean percentage of stained cells (triplicates) are shown; significant
differences between untreated LnStr/LuFb and LnStr/LuFb co-cultured with ASMLwt exosomes: black *; significant differences between
untreated LnStr/LuFb and LnStr/LuFb co-cultured with ASML-CD44vkd exosomes: gray *. (C and D) Experiments were repeated three
times revealing comparable results. Abbreviations: MMP3, matrix metalloproteinase 3; CXCL2, chemokine ligand 2; CCL20, chemokine
ligand 20; MT1a, metallothionein; PTGS2, prostaglandin-endoperoxide synthase 2; alpha2M, alpha-2-macroglobulin; RGS2, regulator of
G-protein signaling 2; PRG4, proteoglycan 4; VCAM1, vascular cell adhesion molecule–1/CD106; ANKRD1, ankyrin repeat domain 1;
PLA2g2A, phospholipase A2 group 2A; SOD2, superoxide dismutase 2; CCL19, chemokine ligand 19; SLC40A1, solute carrier family 39;
GADD45g, growth arrest and DNA-damage-inducible 45γ; SLPI, secretory leukocyte peptidase inhibitor; BTG2, B-cell translocation gene
2; ICAM1, intercellular adhesion molecule 1/CD54; MYH11, myosin heavy chain 11; AMACR, α-methylacyl-CoA racemase; MPG, matrix
Gla protein; ADAMTS8, a disintegrin-like and metalloprotease with thrombospondin type 1, motif 8; RASl11b, RAS-like family 11 mem-
ber B; EDN1, endothelin 1; SSB-1, SPRY domain-containing SOCS box protein SSB-1; FABP3, fatty acid binding protein 3; FST, follis-
tatin; ADAMTS5, ADAMTS, motif 5; CXCL1, chemokine ligand 1; SCBG1A1, secretoglobin, family 1A, member 1; PPP1R3c, protein
phosphatase 1, regulatory subunit 3C; CD49a, integrin α1; MDR1, ATP-binding cassette, subfamily B, member 1; KRT2-7, keratin com-
plex 2; NBI1, neuroblastoma suppression of tumorigenicity; latent TGFβ, latent TGFβ binding protein.
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(Figure 5A). Increased mRNA signals were unexpected, as with few
exceptions the signal strength in exosomes was lower than in LnStr
(Figure 5B), and for 36 of the 38 mRNAs upregulated in ASMLwt
exosome–treated LnStr cells, the exosomal mRNA signal strength
was low (<1000). Nonetheless, qRT-PCR confirmed ma-
trix metalloproteinase 3 (MMP3), metallothionein (MT1a), and a
disintegrin-like and metalloprotease with thrombospondin type 1
(ADAMTS1) up-regulation in LnStr after co-culture with ASML
exosomes (Figure 5C ). From 18 mRNAs, where expression was con-
trolled at the protein level, 14 were significantly upregulated in LnStr
and 13 in LuFb after co-culture with ASMLwt exosomes. Similar
effects were observed after co-culture with ASML-CD44vkd exosomes
(Figure 5D).
In view of the low levels of exosomal mRNA and the inefficient
translation in host cells, it becomes unlikely that altered mRNA/
protein expression in exosome-treated targets derives from transferred
exosomal mRNA translation. There are three possible explanations:
exosome binding and/or uptake stimulates target cells to initiate gene
Figure 6. Reduced mRNA recovery and protein expression in LnStr and LuFb after co-culture with ASMLwt and ASML-CD44vkd exo-
somes: mRNA analysis was performed as described in Figure 5. (A) mRNA whose expression was reduced in LnStr by more than
two-fold after co-culture with exosomes. (B) Confirmation of mRNA down-regulation (selected examples) by qRT-PCR (mean of three
replicate samples with SD < 0.25, indicating reliability according to the software program for ΔCT) and (C) at the protein level in LnStr
and LuFb by flow cytometry (mean percentage of stained cells, triplicates); examples are grouped according to reduced mRNA recovery
after co-culture with ASMLwt and ASML-CD44vkd or ASMLwt or ASML-CD44vkd exosomes; significant differences between untreated
LnStr/LuFb and LnStr/LuFb co-cultured with ASMLwt exosomes: black *; significant differences between untreated LnStr/LuFb and
LnStr/LuFb co-cultured with ASML-CD44vkd exosomes: gray *. (B and C) Experiments were repeated three times revealing comparable
results. mRNA microarray analysis confirmed the strong impact of exosomes on mRNA recovery in target cells. Many effects were
observed with ASMLwt and ASML-CD44vkd exosomes, but distinct regulations, e.g., of cyclin B2, TRAF4, IL1RI1, and Id2 by ASMLwt
and ASML-CD44vkd exosomes were also observed. Abbreviations: CEACAM10, CEA-related cell adhesion molecule 10; MCPT1, mast
cell protease; BCAS1, breast carcinoma amplified sequence; FABP2, fatty acid binding protein 2; FXYD3, FXYD domain-containing ion
transporter regulator 3; TRAF4, TNF receptor–associated factor 4; cdh17, cadherin-17; MAL, myelin and lymphocyte protein; Cdc2a, cell
division cycle 2 homolog A; GALs4, galactose binding soluble 4 lectin; Krt1-19, keratin complex 1, acidic, gene 19; Kifc1, kinesin family
member C1; 15-HPGD, 15-hydroxyprostaglandin dehydrogenase; Csrp2, cysteine and glycine-rich protein 2; GCNT3, glucosaminyl
(N -acetyl) transferase 3; AT1A, angiotensin II receptor 1; NPPb, natriuretic peptide precursor type B; EDG2, endothelial differentiation,
lysophosphatidic acid G protein–coupled receptor 2; CDC20, cell division cycle 20 homolog; GJA4/GJB2, GAP junction membrane channel;
MXD3, Max dimerization protein; IL1Rl1, interleukin-1 receptor-like 1; CA5b, carbonic anhydrase VB; CD104, integrin β4; KLF4, Kruppel-like
factor 4; PTPRR, protein tyrosine phosphatase, receptor type; Id2, inhibitor of DNA binding 2; PPARG, peroxisome proliferator–activated
receptor gamma;MuCdhl, mucin and cadherin like; SLC22a18, tumor-suppressing subtransferable candidate 5; SULT1A1, sulfotransferase
family 1A; ALDH3α1, aldehyde dehydrogenase family 3, member A1.
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transcription/silencing; transferred mRNA provides a trigger for
master gene transcription; or miRNA allows for up-regulation of genes
through silencing regulatory mRNA. We have not yet explored the
first and second possibilities but searched for the impact of miRNA.
The Impact of Exosomal miRNA on LnStr and LuFb
A direct impact of exosomal miRNA on target cell mRNA was
supported by the finding that 11 mRNAs with high signal strength
in LnStr become downregulated by ASMLwt and 18 mRNAs by
ASML-CD44vkd exosomes (Figures 5A and 6A). Including mRNA
with lower signal strength, 31 LnStr mRNAs were downregulated
by ASMLwt and/or ASML-CD44vkd exosomes. Similar to upregulated
mRNA, mRNA down-regulation was mostly seen after co-culture with
ASMLwt and ASML-CD44vkd exosomes, although the degree of down-
regulation differed. Down-regulation of MAL and cdh17 in LnStr co-
cultured with ASMLwt exosomes was confirmed by qRT-PCR, and at
the protein level for MAL and GALs4 (ASMLwt and ASML-CD44vkd
exosomes), five of six genes were downregulated by ASMLwt exosomes
[periostin, aniline, cyclin B2, TNF receptor–associated factor 4
(TRAF4), and Cdc2a] and five of five genes were downregulated
by ASML-CD44vkd exosomes (claudin-6, neuropilin, ALDH3α1,
IL1R1, and CA5b; Figure 6, B and C).
Curious, if exosomal miRNA might account for mRNA down-
regulation, we searched (targetscan.org) for exosomal miRNA for
which the target mRNA was downregulated in exosome-treated
LnStr. We selected 20 mRNAs with high signal strength that were
significantly downregulated after co-culture with ASMLwt or ASML-
CD44vkd exosomes. Arbitrarily taking these 20 mRNAs as 100%
(inner circle), the relative reduction in co-cultures with ASMLwt
(middle circle) and ASML-CD44vkd exosomes (outer circle) was
calculated (Figure 7A). Expectedly, several exosomal miRNAs could
potentially account for down-regulation of these 20 mRNAs in
LnStr; only the miRNAs potentially targeting the selected LnStr
mRNAs are presented. The contribution of these miRNAs to the
total recovery of exosomal miRNA is shown in the arrowed small
circles (Figure 7B). As MAL, cdh17, and TRAF4 mRNA were strongly
downregulated and, potentially targeting miR-494, miR-542-3p and
miR-290 were enriched in ASMLwt exosomes, we explored the effect
of miRNA transfection on LnStr. miR-26b and miR-204, more abun-
dant in ASML-CD44vkd exosomes and known to target Kruppel-like
factor 4 (KLF4), whose expression was more strongly reduced in
Figure 7. Assignment of exosomal miRNA toward downregulated mRNA in LnStr. (A) Semiquantitative presentation of 20 abundant
LnStr mRNAs that were strongly downregulated in exosome-treated LnStr. These 20 mRNAs have arbitrarily been taken as 100% (inner
circle). The relative reduction by co-culturewith ASMLwt exosomes is shown in themiddle circle and that by ASML-CD44vkd exosomes in the
outer circle. (B) Exosomal miRNA potentially targeting these 20 downregulated LnStr mRNAs again were arbitrarily taken as 100%, their
actual contribution to the total exosomal miRNA being indicated by the arrowed small circles. miRNA are assigned only for more than 50%
reduced mRNA. Text box colors in A corresponds to text colors in B to facilitated coordination of potential effector miRNA in ASMLwt (upper
right) and ASML-CD44vkd exosomes (lower right) to the downregulated mRNA (abbreviations correspond to Figure 6).
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ASML-CD44vkd–treated LnStr, served as controls as well as MT1a,
which is strongly upregulated in exosome-treated LnStr. qRT-PCR
revealed down-regulation of MAL and cdh17 by miR-494, of cdh17
and TRAF4 by miR-542-3p, of TRAF4 by miR-290, and of KLF4
by miR-204 and miR-26b. The latter also affected cdh17, which is
not a direct miR-26b target (Figure 8A). The findings were confirmed
for MAL and TRAF4 protein expression in LnStr: miR-494 trans-
fection downregulated MAL; miR-542-3p and miR-290 transfection
downregulated TRAF4 expression, although with a lower efficacy than
ASMLwt exosomes; miR-26b and miR-204 transfection did not affect
MAL; only miR-26b transfection weakly affected TRAF4 expression
(Figure 8B). Furthermore, a 3′UTRMAL and cdh17 luciferase reporter
assay confirmed that MAL and cdh17 are targeted by miR-494 and
cdh17 by miR-542-3p. Co-culture with ASMLwt exosomes exerted a
stronger effect than a single miRNA, indicating that additional exo-
somal miRNA may regulate cdh17 and MAL expression (Figure 8C).
Thus, functional exosomal miRNA is transferred in LnStr and affects
target gene expression.
MT1a mRNA up-regulation in LnStr upon co-culture with exo-
somes, but also by transfection with miR-494 and miR-542-3p, sup-
ported miRNA-mediated down-regulation of target mRNA to affect
expression of genes regulated by the primary miRNA target. With
the expression of several proteases being upregulated after co-culture
with ASML exosomes despite low exosomal mRNA expression, we
finally asked whether miRNA silencing of cdh17 might be accom-
panied by protease up-regulation, MMP2 and MMP9 up-regulation
Figure 8. Functional activity of exosomal miRNA. (A and B) Impact of miR-494, miR-542-3p, miR-290, miR-204, and miR-26b transfection
on MAL, cdh17, KLF4, and TRAF4 and, for comparison, MT1a expression in LnStr as revealed 48 hours after transfection or co-culture with
exosomes by (A) qRT-PCR (mean of three replicate samples with SD< 0.25, indicating reliability according to the software program for ΔCT)
and (B) flow cytometry. (A) Significant differences in mRNA recovery between untreated and miRNA-transfected LnStr: *; (B) significant
differences between untreated and miRNA-transfected LnStr in the mean percentage of stained cells (triplicates, two experiments): *;
significant differences in the mean intensity of staining (triplicates, two experiments): s. (C) HEK293 cells were transfected with the dual-
luciferase pmiRGlo vector containing the 3′UTR of MAL or cdh17 and were co-transfected with miR-494 or miR-542-3p (10 nM) or were co-
cultured with ASMLwt exosomes (20 μg). Firefly and, for normalization, Renilla luciferase activity was evaluated after 48 hours in a FLUOstar
OPTIMA luminometer. The relative luciferase activity and P values for miR co-transfection or ASMLwt exosome co-culture are shown. Sig-
nificant differences are indicated. (D and E) Impact of cdh17 down-regulation in LnStr by miR-494 and/or miR-542-3p or, as control, miR-290
transfection on MMP2, MMP3, MMP9, and MMP14 expression as revealed by (D) flow cytometry and (E) representative example of zymo-
graphy of LnStr culture supernatant, which confirmed MMP2 and MMP3 up-regulation. (D) Significant differences between untreated and
miRNA-transfected LnStr in the mean percentage of stained cells (triplicates, two experiments): *; significant differences in the mean in-
tensity of staining (triplicates): s. (E) The MMP ratio (mean of three experiments) compared to untreated LnStr is shown; significant differ-
ences: *. Transferred exosomal miRNA affects selective RNA expression in LnStr. As demonstrated for cdh17, exosomal miRNA repression
of target mRNA can be accompanied by release of suppression for genes regulated by the primary miRNA target.
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being described to accompany cdh17 down-regulation [47]. Though
expression of MMP9 was unaffected, MMP2 and MMP3 were
strongly and MMP14 was weakly upregulated in miR-494, miR-542-
3p, and miR-494 plus miR542-3p but not in control miR-290–
transfected LnStr. miR-542-3p exerted a strong effect on MMP2 and
miR-494 on MMP3 expression. MMP14 expression was equally
affected by both miRNAs. Up-regulation of MMP2 and MMP3
in miRNA-transfected LnStr was confirmed by zymography (Figure 8,
D and E).
Thus, tumor exosome miRNA strongly affects non-transformed
target cells through silencing mRNA including mRNA up-regulation
by release from repression by directly targeted mRNA.
Overview of Exosome-Modulated Gene Expression
in Target Cells
Finally, we searched for functional activities of transcripts sig-
nificantly upregulated by ASMLwt exosomes in LnStr. For six genes,
no or very preliminary data on functional activity were found (not
settled). There has been no hint for up-regulation of oncogenes. In-
stead, increased protease activity, pronounced adhesion molecule and
chemokine ligand expression, and up-regulation of cell cycle– and
angiogenesis-promoting genes and of genes engaged in oxidative stress
response all fit the demands of metastasizing tumor cells for settle-
ment and growth (Figure W6).
Taken together, the transfer of exosomal miRNA has severe con-
sequences on target cell gene expression, where miRNA-induced
changes could facilitate metastasizing tumor cell settlement in pre-
metastatic organs.
Discussion
Tumor cells can establish a niche for metastasizing cells preceding their
arrival [3–5]. Tumor exosomes, carrying growth factors, cytokines/
receptors, and matrix degrading enzymes and transferring tumor
mRNA and miRNA [8,12,48], could well provide the essential trigger
[6–8,10–12,15,16,49]. We showed [6] that poorly metastatic ASML-
CD44vkd cells regain metastatic potential after conditioning rats with
ASMLwt or ASML-CD44vkd exosomes together with ASMLwt-CM−exo.
We here demonstrate that ASML exosomes are taken up in vivo and
that exosomal miRNA strongly affects favorite targets shown for LnStr
and LuFb. We particularly want to discuss two points: 1) Though
exosomes are characterized by a protein profile that is rich in molecules
located in internalization-prone membrane domains and molecules
engaged in fission, scission, and vesicular transport [14,22,24,25], a
single protein that is involved in gene transcription/posttranscriptional
regulation, like CD44v, can have significant bearing on the composi-
tion of exosomal proteins, mRNA, and miRNA, even if not involved in
directly guiding proteins or harboring mRNA/miRNA into MVB; 2)
though we did not yet explore the impact of exosome binding– or
uptake-induced signal transduction, our data support exosomal
miRNA strongly affecting target cells.
Exosome Proteins, mRNA, and miRNA
Our findings confirm that recruitment of mRNA into MVB is a
selective process such that the exosomal mRNA profile does not reflect
that of the donor cell [18,22]. Only 1500 mRNAs were recovered in
ASML exosomes compared to >8000 in ASML cells. This difference
might be an overestimate as the mRNA isolation kit that was used mean-
while was demonstrated to unproportionally enrich for small RNA [46].
Nonetheless, the relative abundance of mRNA in exosomes and cells
differed and there has been a significant number of mRNA that was en-
riched in exosomes compared to cells, strengthening the selective recruit-
ment of mRNA into MVB. However, with few exceptions, the ratio of
exosomal ASMLwt versus ASML-CD44vkd mRNA did not differ signif-
icantly from that in cells. From there, we conclude that CD44v or asso-
ciated molecules or molecules whose expression is regulated by CD44v
may not be engaged in mRNA recruitment into MVB/exosomes. As
already demonstrated [6,45], this also accounts for exosomal proteins.
Protein expression differs between ASMLwt and ASML-CD44vkd exo-
somes. However, these changes are also seen at the cellular level. How-
ever, CD44v/asssociated molecules clearly contribute to transcription of
several genes recovered in exosomes, as the mRNA profile of ASMLwt
versus ASML-CD44vkd cells showed strong differences.
The cellular ASMLwt and ASML-CD44vkd miRNA profiles also dif-
fer, suggesting engagement of CD44v/associated molecules in miRNA
transcription or posttranscriptional regulation. Thus, the tumor sup-
pressors let-7b, let-7d, let-7e, and miR-101 were increased in ASML-
CD44kd exosomes and cells. It has been suggested that tumor cells get
rid of let-7 through exosomes [50]. Alternatively, our findings point
toward CD44v to be engaged in downregulating let-7 and miR-101.
Irrespective of the underlying mechanism, the higher level of let-7 in
ASML-CD44vkd exosomes is in line with the reduced metastatic capac-
ity of these cells [43]. Notably, too, miR-34a, which suppresses tumor
growth by CD44 down-regulation [51], was very low in ASMLwt exo-
somes and cells but abundant in ASML-CD44vkd exosomes, which
argues, in turn, for CD44v or associated molecules to be engaged in
miR-34a silencing. Metastasis-promoting miR-494 and miR-21 and
apoptosis-regulating miR-24-1 [52–54] are also abundant only in
ASMLwt exosomes. miRNA transcription and/or posttranscriptional
regulation appear also to be affected by CD44v-associated c-Met [6],
which supports miR-103 transcription [55] that is more than two-fold
increased in ASMLwt exosomes. CD44v-related changes are mostly
reflected in the exosomal miRNA profile such that miRNA reduced
in ASML-CD44vkd cells are also lower in ASML-CD44vkd than
ASMLwt exosomes. Irrespective of a possible additional involvement
of CD44v in MVB recruitment, CD44v clearly is engaged in miRNA
transcription/posttranscriptional regulation.
Taken together, proteins and mRNA of genes, whose expression is
regulated by CD44v (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE34739) [6,43,45], are recovered at a reduced level in
ASML-CD44vkd exosomes. Yet, there is no evidence for CD44v con-
tributing to protein or mRNA recruitment into MVB. Our data also
indicate an engagement of CD44v in miRNA transcription/silencing/
posttranscriptional regulation. Exosomal miRNA having a significant
impact on target cells, the finding that a molecule not actively engaged
in exosome assembly/transport can strongly affect the exosome com-
position requires detailed exploration that may provide key answers to
metastasis-promoting CD44v activities.
Exosomal mRNA, miRNA, and Target Cell Fate
LnStr mRNA and protein recovery was altered by co-culture with
ASML exosomes. Besides mRNA/miRNA, exosomal proteins can
affect target cells as demonstrated for dendritic cell exosome–promoted
T cell activation, which proceeds through exosome binding–initiated
signal transduction and gene transcription [20]. Exosome binding–
initiated signal transduction will be facilitated by exosomal ligands be-
ing located in internalization-prone membrane domains [33,56], which
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are enriched in receptor tyrosine kinases, phosphatases, proteases, and,
at the inner membrane, linker and signal transduction molecules [57].
Without question, target cell stimulation by tumor exosome binding
and uptake requires to be evaluated. Nonetheless, we did not observe
a measurable impact of exosomal proteins taken up by target cells [58]
and high protein expression in ASMLwt exosomes is hardly reflected
by increased recovery in target cells. Therefore, we proceeded to ask for
the impact of uptaken mRNA and miRNA. Though there are discrete
differences in the mRNA and, more markedly, the miRNA profile of
ASMLwt and ASML-CD44vkd exosomes, it should be mentioned
that we were mostly concerned about the impact of exosomal mRNA
and miRNA in general and controlled at the functional level only
ASMLwt exosomes.
Similar to our findings on exosomal proteins, our data argue
against transferred exosomal mRNA to account for increased target cell
mRNA: 1) With few exceptions, mRNA levels are significantly higher
in LnStr than exosomes; 2) mRNA levels become unproportionally
upregulated, e.g., the MMP3 mRNA level in LnStr increased 13-fold
upon exosome uptake, but the mRNA level in exosomes was about
10% that in LnStr, excluding the effect to be due to transferred
exosomal mRNA; 3) mRNA levels in LnStr remained increased for
48 hours. RNA recovery in LnStr unlikely deriving from transferred
exosomal mRNA points toward exosome-initiated transcription, which
remains to be explored, or toward miRNA contributing to mRNA up-
regulation by silencing repressive mRNA.
In LnStr co-cultured with ASML exosomes, several mRNA became
strongly downregulated. Though it is not possible to differentiate
between direct and indirect effects, as most miRNAs have multiple
targets, there is evidence for a direct impact of exosomal miRNA.
ASMLwt and ASML-CD44vkd exosomes show distinct miRNA pro-
files and reduced mRNA levels in LnStr co-cultured with ASMLwt
versus ASML-CD44vkd exosomes overlap only partially. In addition,
miRNA targeting mRNA selectively downregulated by ASMLwt exo-
somes were more abundant in ASMLwt than ASML-CD44vkd exo-
somes and the ASML-CD44vkd exosome miRNA that could
potentially target the 18 mRNAs downregulated in LnStr accounts
for more than 60% of the total miRNA.
We focused on abundant miR-494, potentially targeting MAL and
cdh17, and miR-542-3p, targeting cdh17 and TRAF4. MAL can
contribute to differentiation and apical sorting [59,60] and cdh17
to tumor growth/Wnt signaling [61]; TRAF4 exerts morphogenetic
functions [62]. LnStr transfection with these miRNAs was accompa-
nied by down-regulation of the predicted target(s), which also ac-
counted for miR-204 and miR-26b transfection that downregulated
KLF4, which can be opposingly affected by miRNA in normal versus
malignant cells [63,64]. We confirmed by miRNA transfection and
by luciferase reporter assay in co-culture with exosomes or transfec-
tion with miRNA that the transfer of exosomal miRNA can directly
affect target cell mRNA.
Finally, significant up-regulation of mRNA in exosome-treated
LnStr pointed toward mRNA up-regulation through miRNA silencing
regulatory mRNA. Altered protease expression being a dominating fea-
ture in ASML-exosome–treated LnStr and in vivo in draining lymph
nodes after ASMLwt-CM application [6], and cdh17 down-regulation
being known to promote MMP2 and MMP9 up-regulation [47], the
finding that cdh17 down-regulation in miR-494 and miR-542-3p
transfected LnStr was accompanied by MMP2, MMP3, and
MMP14 up-regulation strengthens a direct impact of transferred exo-
somal miRNA on target cells.
Conclusion
Tumor exosomes being of central importance in premetastatic niche
preparation [6,16], we characterized exosomes from a metastatic tumor
line and evaluated their mode of action. CD44v contributing to the
cross talk between tumor exosomes and host stroma, we additionally
defined the impact of CD44v on the exosome composition.
As summarized in Figure W7, tumor exosomes contain a restricted
mRNA and miRNA panel and there is evidence that CD44v contrib-
utes to shaping the exosomal protein, mRNA, and miRNA profiles
by regulating gene and miRNA transcription/posttranscriptional reg-
ulation without a direct impact on recruitment into MVB/exosomes
(Figure W7A). Exosomes reach premetastatic organs in vivo, bind, and
are taken up by selected targets (FigureW7B). Exosome binding/uptake
severely alters target cells. This can be due to exosome binding–initiated
target modulation or target cell activation, which has not been explored
in the present manuscript (Figure W7C), and to transferred exosomal
miRNA, where we provide for the first time evidence that not only the
direct miRNA target but also release from repression by the primary tar-
get significantly contributes to target cell reprogramming by tumor exo-
somes (FigureW7D). Finally, supporting the concept of a central role of
tumor exosomes in metastasis, exosomal miRNA from a metastasizing
tumor line, though not being oncogenic, preferentially regulates mRNA,
which contributes to establishing a premetastatic niche (Figure W6).
Exosomes are discussed as a most potent gene delivery system. Our
findings support this hypothesis and suggest that competing tumor exo-
somes could well be a promising therapeutic option by preventing
establishing a premetastatic niche. Beyond this, tailored exosomes might
allow to rescind tumor exosome–induced host cell modulation.
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Table W1. List of Antibodies.
Antibody Supplier Antibody Supplier
α6β4 Clone B5.5 [1] EpCAM Clone D5.7 [1]
ADAM10 Santa Cruz Biotechnology (Heidelberg, Germany) Fibulin Santa Cruz Biotechnology
ADAM17 Santa Cruz Biotechnology Fibronectin BD (Heidelberg, Germany)
ADAMTS1 Santa Cruz Biotechnology Follistatin Santa Cruz Biotechnology
ADAMTS5 Santa Cruz Biotechnology GADD45G Santa Cruz Biotechnology
ADAMTS8 Santa Cruz Biotechnology Gal.bind. 4 Santa Cruz Biotechnology
ALDH3a1 Santa Cruz Biotechnology Hyaluronan Rockland (Gilbertsville, PA)
Anillin Santa Cruz Biotechnology HGF Santa Cruz Biotechnology
bFGF Oncogene (Boston, MA) HGDF Santa Cruz Biotechnology
BTG2 Santa Cruz Biotechnology IGF Santa Cruz Biotechnology
CA5B Santa Cruz Biotechnology IL1Rl1 Santa Cruz Biotechnology
C4.4A Clone C4.4 [1] Laminin 1 Rockland
Caveolin Santa Cruz Biotechnology MAL Santa Cruz Biotechnology
CD9 BD MDR1 Santa Cruz Biotechnology
CD11a BD MMP2 Dianova (Hamburg, Germany)
CD11b Clone Ox42 (EAACC)* MMP3 Santa Cruz Biotechnology
CD11c Clone Ox41 (EAACC)* MMP9 Dianova
CD18 BD MMP13 Dianova
CD24 BD MMP14 Dianova
CD29 BD Metallothio. Santa Cruz Biotechnology
CD44s Clone Ox50 (EAACC)* Neuropilin Santa Cruz Biotechnology
CD44v6 Clone A2.6 [1] Osteopontin Santa Cruz Biotechnology
CD49a BD Palladin Santa Cruz Biotechnology
CD49b BD Pan cadherin Santa Cruz Biotechnology
CD49c BD PDGF BD
CD49d BD PDGFR BD
CD49e BD Periostin Santa Cruz Biotechnology
CD49f Abcam (Cambridge, United Kingdom) PG-Synth. 3 Santa Cruz Biotechnology
CD53 Clone Ox44 (EAACC)* Phospholip.A2 Santa Cruz Biotechnology
CD54 Biozol (Eching, Germany) Properdin Santa Cruz Biotechnology
CD56 BD SDF1 Abcam
CD61 Biozol SLPI Santa Cruz Biotechnology
CD62L BD SOD2 Santa Cruz Biotechnology
CD63 BD Tenascin LabVision (Fremont, CA)
CD81 Santa Cruz Biotechnology TF Santa Cruz Biotechnology
CD104 BD TGFβ Santa Cruz Biotechnology
CD106 Biozol TRAF4 Santa Cruz Biotechnology
CD151 [2] uPA Calbiochem (Darmstadt, Germany)
Cdc2a Santa Cruz Biotechnology uPAR Calbiochem
Claudin-4 Santa Cruz Biotechnology VEGF Biotrend (Köln, Germany)
Claudin-6 Santa Cruz Biotechnology VEGFR1 Biotrend
Collagen I Rockland VEGFR2 Biotrend
Collagen II LabVision Vitronectin Biotrend
Collagen IV Rockland vWF Abcam
CXCR4 Santa Cruz Biotechnology mIgG† Dianova
CyclinB2 Santa Cruz Biotechnology mIgM† Dianova
D6.1A Clone D6.1 [1] Rabbit IgG† Dianova
Endothelin BD Goat IgG† Dianova
Streptavidin† Dianova
References:
[1] Matzku S, Wenzel A, Liu S, and Zöller M (1989). Antigenic differences between metastatic and non-metastatic rat tumor variants characterized by monoclonal antibodies. Cancer Res 49, 1294–1299.
[2] Claas C, Wahl J, Orlicky D, Karaduman H, Schnölzer M, Kempf T, and Zöller M (2005). The tetraspanin D6.1A and its molecular partners on rat carcinoma cells. Biochem J 389, 99–110.
*EAACC, European Association of Animal Cell Cultures, Porton Down, United Kingdom.
†Secondary antibodies and streptavidin were fluorescein isothiocyanate, phycoerythrin (PE), biotin, or HRP labeled.
Table W2. Primers.
Primers for qRT-PCR
GAPDH
Forward primer: cttctccatggtggtgaagac
Reverse primer: gaccccttcattgacctcaac
Cdh17
Forward primer: cctggtggtctctgtgaagg
Reverse primer: gtgattttgatggggtgagg
MAL
Forward primer: ttctccgtcttcgtcacctt
Reverse primer: gtctccccaccatgagtacc
KLF4
Forward primer: gcaagtcccctctctccatt
Reverse primer: ggtaaggtttctcgcctgtg
MMP3
Forward primer: ggctgaagatgacagggaag
Reverse primer: caatggcagaatccacactc
MT1a
Forward primer: accccaactgctcctgct
Reverse primer: acttgtccgaggcaccttt
ADAMTS1
Forward primer: gcccactgcttctactctgg
Reverse primer: gtgcgattgactcctccttc
TRAF4
Forward primer: gctgctggaggctgtcaa
Reverse primer: atctgtgctgggttcctg
4.5SRNA
Forward primer: aatgccccaaaaacagtcaa
Reverse primer: acctccagttgaaccagcac
C4.4A
Forward primer: attcacactcagcggttcct
Reverse primer: gtggtgggcttgatggtag
Stem loop primers
Universal reverse miRNA primer: 5′ gtgcagggtccgaggt 3′
Stem loop miR-300-5p:
Forward primer: 5′ gttggctctggtgcagggtccgaggtattcgcaccagagccaacacaaag 3′
Stem loop miR-296:
Forward primer: 5′ gttggctctggtgcagggtccgaggtattcgcaccagagccaacggagag 3′
Stem loop miR-300-5p:
Forward primer: 5′ gtttggttgaagagaggttatc 3′
Stem loop miR-296:
Forward primer: 5′ ttggagggttgggtggag 3′
Oligos and primers for the reporter assay
300-5p binding oligo
Sense: 5′ aaactagcggccgctagtacaaaggataacctctcttcaat 3′
Antisense: 5′ ctagattgaagagaggttatcctttgtactagcggccgctagttt 3′
Cdh17
3′UTR cdh17 fw Pme1: gtttaaactccctttctgtttccacctg
3′UTR cdh17 rev Xba1: tctagacaccacgtacatgctttcgt
MAL
3′UTR MAL fw Pme1: gtttaaacgacagcagattgggagct
3′UTR MAL rev Xba1: tctagatgttgggtgaatttcagtg
Sequences of the 3′UTR with binding sites and SVR score
3′UTR MAL
gacagcagattgggagctgaaacccagagcaattaactggtcagcctgtcttccccattaacttcctggaacagactgaatggtggagaaaagaaaa
caagccaaaagaaaacaaaacagacacaaaaacaaaaggaaaccatgttcgagtctcttgggtgttacgtttaccttctgttagggtttagggcttg
ctgaatttaacttccagccaaaggaggaaagagttgtcttggcgggccctttctgcccttgaccaggacagtgggtgggagcttggaaccttgatc
tgaagaaatgacaatttccccttgacccttggagcaggtcctaacaattgcctttcggaattttccacaagctctttgcaccactcatcccctggcata
tcttagattttgtggatagtctaggtgtcacaggcactgaaattcacccaaca
gacagcagattgggagc: target site miR-494 (mirSVR score: −0.9472)
3′UTR Cdh17
tccctttctgtttccacctgcgccccctgatctcagcattacattaaatttaaaatgtgtcacacaaaagaacaaagtgaagtccttggggggggtgtt
gctaagtggacagccttattctttagcacaaacaacagcttctctgtgttgtcatctttaatagaggtcctccagcttggctatggtgtagaccctggg
gaggtatcaaatacaactgccgtgtttcaagaaagacctacttcatgaggcacaggaactgacgagctgtctgggtttactcactactccgtgctta
catacatgctgtacatgttttatttgtatattgaagttttgttatatatttatcatgtggaggaaagacgaaagcatgtacgtggtg
attaaatttaaaatgtgtcaca: target site miR-542-3P (mirSVR score: −0.1085)
atacatgctgtacatgtttta: target site miR 494 (mirSVR score: −0.1085)
Table W3. mRNA Recovery in ASMLwt and ASML-CD44vkd Exosomes (Signal Strength 10,000).
mRNA Mean Signal Strength*
ASMLwt Exosomes ASML-CD44vkd Exosomes
Acidic ribosomal phosphoprotein P0 (Arbp) 36,537 34,209
Pred. similar to LRRG00135 28,102 17,532
Pred. similar to Ab2-143 26,757 13,956
Pred. similar to 60S ribosomal protein L37a 25,511 27,156
Pred. similar to LRRG00135 25,318 15,450
Pred. similar to testin (LOC503278) 24,223 12,457†
Pred. similar to RIKEN cDNA 2410116I05 23,944 21,405
Ribosomal protein S15a (Rps15a) 22,854 25,011
Pred. ribosomal protein L27a (Rpl27a) 21,294 25,079
Pred. ribosomal protein L37a (Rpl37a) 20,655 26,661
Pred. similar to 60S ribosomal protein L7a 18,819 24,078
Ribosomal protein S14 (Rps14) 18,335 22,643
Eukaryotic translation elongation factor 1 alpha 1 17,840 20,172
Pred. similar to ORF4 17,709 8,172†
Pred. similar to 60S ribosomal protein L23a 17,248 22,830
Pred. similar to ribosomal protein L19 16,799 21,770
Pred. similar to ORF4 (LOC361942) 16,503 7,596†
Ribosomal protein S18 (Rps18) 16,501 16,624
Pred. similar to testis-derived transcript 16,125 25,111
Pred. ribosomal protein L10 (Rpl10) 16,056 14,972
Ribosomal protein L41 (Rpl41) 15,816 15,564
Pred. S100 calcium-binding protein A11 (S100a11) 15,812 20,179
Pred. similar to 40S ribosomal protein S3 15,623 14,168
Ribosomal protein S4, X-linked (Rps4x) 15,608 22,525
Pred. ribosomal protein s25 (Rps25) 15,597 15,107
Pred. similar to Ac1262 15,361 6,541†
Ribosomal protein L9 (Rpl9) 15,328 15,018
Tumor protein, translationally controlled 1 (Tpt1) 14,796 15,898
Pred. similar to 60S ribosomal protein L7a 14,785 18,844
Ferritin, heavy polypeptide 1 (Fth1) 14,268 13,168
Ribosomal protein L29 (Rpl29) 14,249 19,063
Eukaryotic translation elongation factor 1 alpha 1 14,047 15,670
Pred. ribosomal protein S5 (Rps5) 13,772 12,954
Ribosomal protein L3 (Rpl3) 13,516 17,927
Laminin receptor 1 (ribosomal protein SA) (Lamr1) 13,281 16,180
Ribosomal protein S3 (Rps3) 13,274 13,387
Ribosomal protein L32 (Rpl32) 13,223 14,601
Ribosomal protein L6 (Rpl6) 13,023 13,800
Pred. similar to glyceraldehyde-3-phosphate dehydrogenase 12,883 20,653
Ribosomal protein S10 (Rps10) 12,629 15,551
Ribosomal protein S29 (Rps29) 12,375 14,993
Ribosomal protein S20 (Rps20) 12,191 16,162
Pred. Similar to 60S ribosomal protein L9 12,045 11,228
Pred. similar to 60S ribosomal protein L6 (neoplasm-related protein C140) 12,002 11,535
Pred. similar to ribosomal protein S7 11,952 16,878
Pred. similar to 40S ribosomal protein S20 11,767 13,423
Pred. similar to ribosomal protein S23 11,758 14,377
Pred. similar to ribosomal protein S26 11,619 11,565
Ribosomal protein L17 (Rpl17) 11,387 14,337
Pred. similar to ribosomal protein L15 11,382 10,145
Ubiquitin A-52 residue ribosomal protein fusion product 1 11,277 10,050
Pred. similar to Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived) 11,094 13,392
Ribosomal protein S8 (Rps8) 11,085 17,872
Ribosomal protein L22 (Rpl22) 11,074 15,648
Pred. similar to ribosomal protein L31 11,007 12,825
Pred. similar to 60S ribosomal protein L32 10,602 12,524
Ribosomal protein, large, P1 (Rplp1) 10,529 9,656
Ribosomal protein S26 (Rps26) 10,390 11,011
Peptidylprolyl isomerase A (Ppia) 10,363 18,435
Ribosomal protein L27 (Rpl27) 10,242 14,789
Pred. Finkel-Biskis-Reilly murine sarcoma virus ubiquitously expressed (Fau) 10,237 13,329
Pred. similar to 60S ribosomal protein L17 (L23) (amino acid starvation–induced protein) (ASI) 10,203 12,418
Pred. similar to tubulin alpha-2 chain (alpha-tubulin 2) 8,769 20,050†
Actin, beta (Actb) 7,779 14,422
Ribosomal protein L19 (Rpl19) 9,245 12,973
Pred. similar to L-lactate dehydrogenase A chain 8,749 12,938
Pred. capping protein (actin filament) muscle Z-line, α2 9,542 12,599
Pred. similar to ribosomal protein S12 9,387 12,278
Pred. similar to 60S acidic ribosomal protein P2 8,699 12,266
Calmodulin 2 (Calm2) 7,108 12,054
Pred. similar to 60S ribosomal protein L7a 9,513 12,043
Ribosomal protein L21 (Rpl21) 8,710 11,910
Table W3. (continued )
mRNA Mean Signal Strength*
ASMLwt Exosomes ASML-CD44vkd Exosomes
Pred. similar to ribosomal protein L21 9,121 11,850
Pred. triosephosphate isomerase 1 (Tpi1) 5,867 11,739†
PAI-1 mRNA-binding protein (Pairbp1) 5,297 11,647†
Pred. glutathione S -transferase, pi 1 (Gstp1) 7,189 11,480
Pred. similar to glyceraldehyde-3-phosphate dehydrogenase 9,042 11,083
Ribosomal protein S6 (Rps6) 8,109 10,953
Pred. similar to ribosomal protein S19 7,851 10,950
Large subunit ribosomal protein L36a (Rpl36a) 8,625 10,804
Pred. actin, gamma, cytoplasmic (Actg) 8,184 10,751
Similar to 60S ribosomal protein L21 7,251 10,610
Pred. similar to 40S ribosomal protein S3a (V-fos transformation effector protein) 6,252 10,107
Ornithine decarboxylase antizyme 1 (Oaz1) 6,971 10,027
*Mean signal strength was calculated from duplicates, respectively, triplicates, of two independently performed arrays after normalization (Chipster analysis and Agilent annotation). Only exosomal
mRNA with a signal strength of >10,000 is shown.
†Signal strength with a more than two-fold change between ASMLwt and ASML-CD44vkd exosomes.
Table W4. mRNA Expression in ASMLwt and ASML-CD44vkd Cells (Signal Strength 50,000).
mRNA Mean Signal Strength*
ASMLwt Cells ASML-CD44vkd Cells
Hypothetical protein LOC310926 299,044 309,590
Actin, gamma 1 (Actg1) 296,979 221,969
Stefin A2 (Stfa2) 294,927 329,519
Ferritin, light polypeptide (Ftl) 246,290 277,091
Heat shock protein 8 (Hspa8) 246,290 143,431
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) 223,513 182,812
Similar to TRAF-binding protein 217,401 260,333
Testis-derived transcript (Tes) 214,408 143,431
Ferritin light chain 1-like 209,996 217,401
Similar to Ac1147 205,674 221,969
Carcinoembryonic antigen-related cell adhesion molecule 9 (Ceacam9) 202,842 249,728
Similar to glyceraldehyde-3-phosphate dehydrogenase 193,235 180,295
Similar to Rpl7a protein 193,235 179,050
Eukaryotic translation elongation factor 1 gamma (Eef1g) 168,221 91,406
Enolase 1 alpha 165,905 200,050
Ferritin heavy polypeptide 1 (Fth1) 162,491 121,450
Ubiquitin A-52 residue ribosomal protein fusion product 1 (Uba52) 162,491 133,826
Phosphoglycerate mutase 1 (brain) (Pgam1) 159,147 90,775
Similar to sex-determination protein homolog Fem1a 158,048 155,872
Similar to DKFZP434B168 protein 155,872 134,757
Peptidylprolyl isomerase A (cyclophilin A) (Ppia) 151,609 182,812
Coiled-coil-helix-coiled-coil-helix domain containing 2 (Chchd2) 150,562 111,757
Eukaryotic translation elongation factor 1 alpha 1 (Eef1a1) 147,464 151,609
Annexin A2 (Anxa2) 145,433 133,826
Similar to cleavage and polyadenylation factor 73 kDa (CPSF73kDa) 142,441 136,638
Phosphoglycerate kinase 1 (Pgk1) 136,638 100,721
Lactate dehydrogenase A (Ldha) 135,694 95,950
Similar to glyceraldehyde-3-phosphate dehydrogenase 135,694 118,129
Annexin A1 (Anxa1) 129,267 101,421
Heat shock protein HSP 90-beta 125,733 85,878
Transketolase (Tkt) 125,733 107,204
Capping protein (actin filament) muscle Z-line, alpha 2 (Capza2) 122,295 73,732
Eukaryotic translation initiation factor 2B, subunit 2 beta (Eif2b2) 120,611 105,728
Similar to elongation factor 1-alpha 1 (EF-1-alpha-1) 117,313 107,950
Heat shock cognate 71 kDa protein 115,698 66,451
Cathepsin D (Ctsd) 114,105 153,726
Similar to peptidylprolyl isomerase A (cyclophilin A) 110,985 137,588
Actin, beta (Actb) 106,464 48,645†
Ubiquitin C (Ubc) 106,464 146,445
Tumor protein translationally controlled 1 (Tpt1) 104,273 153,726
Eukaryotic translation elongation factor 1 beta 2 (Eef1b2) 100,721 102,127
Ubiquitin B (Ubb) 97,290 95,950
Keratin 18 (Krt18) 95,950 19,216†
Hypothetical gene supported by AF152002 (LOC290595) 94,629 56,267
Tubulin beta 4B class IVb (Tubb4b) 93,976 72,717
Transmembrane emp24-like trafficking protein 10 (Tmed10) 91,406 131,984
Interferon gamma–induced GTPase (Igtp) 90,775 113,317
Table W4. (continued )
mRNA Mean Signal Strength*
ASMLwt Cells ASML-CD44vkd Cells
Similar to elongation factor 1-gamma (EF-1-gamma) 90,775 40,342†
Glutathione S -transferase pi 1 (Gstp1) 86,475 53,232
Heat shock protein 1 (chaperonin 10) (Hspe1) 86,475 50,360
Glutathione peroxidase 2 (Gpx2) 85,285 13,401†
Nucleophosmin (nucleolar phosphoprotein B23, Numatrin) (Npm1) 84,111 92,682
RAN member RAS oncogene family (Ran) 84,111 69,273
Progressive external ophthalmoplegia 1 (Peo1) 81,811 182,812†
Hypothetical protein LOC687872 79,024 71,220
Eukaryotic translation elongation factor 1 delta (Eef1d) 77,398 60,725
Poly(A)-binding protein, cytoplasmic 1 (Pabpc1) 77,398 115,698
Eukaryotic translation elongation factor 2 (Eef2) 76,863 38,166†
Guanine nucleotide binding protein beta polypeptide 2 like 1 (Gnb2l1) 76,332 39,512
Cytochrome c oxidase subunit VIa polypeptide 1 (Cox6a1) 75,281 139,509
NADH-ubiquinone oxidoreductase chain 1 74,761 209,996†
Cytochrome c oxidase subunit VIIa polypeptide 2 like (Cox7a2l) 73,732 64,634
Mitogen-activated protein kinase 3 (MAPK3) 73,732 80,684
Galactoside-binding soluble 3 (Lgals3) 73,223 80,684
Cytochrome b 72,717 181,549†
Non-metastatic cells 2 protein (NM23B) (Nme2) 72,717 65,083
Myosin light polypeptide 6 smooth muscle and non-muscle-like (Myl6l) 72,214 105,728
RT1 class Ia, locus A1 (RT1-A1) 71,716 90,775
Cell division cycle 37 homolog (Cdc37) 69,755 46,988
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 69,755 52,864
CD24 69,273 28,725
Complement component 1q subcomponent binding protein (C1qbp) 69,273 67,847
Hematological and neurological expressed 1 (Hn1) 69,273 22,073†
ATP synthase, H+ transporting, mitochondrial Fo complex C2 (Atp5g2) 68,794 53,602
Phosphoglycerate dehydrogenase (Phgdh) 68,319 72,214
Proteasome subunit beta type 4 (Psmb4) 68,319 39,512
Heat shock protein 90 alpha class B member 1 (Hsp90ab1) 67,378 44,762
Ornithine decarboxylase antizyme 1 (Oaz1) 67,378 62,432
Similar to glyceraldehyde-3-phosphate dehydrogenase 67,378 52,864
ATP synthase, H+ transporting, mitochondrial Fo complex d (Atp5h) 66,913 72,214
Thymosin beta 4. X-linked (Tmsb4x) 66,913 55,109
High-mobility group nucleosome binding domain 1 (Hmgn1) 65,992 85,878
Phosphatidylethanolamine-binding protein 1 (Pebp1) 65,992 76,332
Histidine triad nucleotide-binding protein 1 (Hint1) 65,536 74,761
Eukaryotic translation initiation factor 3, subunit I (Eif3i) 65,083 59,889
ATP synthase subunit d 64,634 65,992
Heat shock protein 1 (chaperonin) (Hspd1) 64,187 50,360
Similar to RIKEN cDNA 3100001N19 (LOC306079) 63,304 54,728
H6 family homeobox 1 (Hmx1) 62,866 59,064
GNAS complex locus (Gnas), transcript variant 3 62,432 120,611
Ly6/Plaur domain containing 3 (Lypd3) 62,432 45,703
ATP synthase, H+ transporting, mitochondrial Fo complex E (Atp5i) 61,573 64,187
Similar to glyceraldehyde-3-phosphate dehydrogenase (LOC305194) 61,573 47,315
Prothymosin alpha (Ptma) 59,475 59,889
Family with sequence similarity 49, member B (Fam49b) 58,251 49,667
ADP-ribosylation factor 5 (Arf5) 57,449 32,317
GTPase IMAP family member 9 (Gimap9) 57,449 75,805
Enolase 1alpha (Eno1) transcript variant 2 57,052 70,728
Cysteine-rich protein 2 (Crip2) 56,658 42,055
ATP synthase, H+ transporting, F1 complex α1 cardiac muscle (Atp5a1) 55,878 67,378
Reactive oxygen species modulator 1 (Romo1) 55,878 32,768
Proteasome 26S subunit ATPase 5 (Psmc5) 55,492 26,801†
TIMP metallopeptidase inhibitor 2 (Timp2) 55,109 214,408†
Cytochrome c oxidase subunit 1 53,975 190,575†
Eukaryotic translation initiation factor 4H (Eif4h) 51,776 21,469†
T-box 21 (Tbx21) 51,776 48,983
Destrin (Dstn) 51,419 36,358
Similar to keratin complex 1 acidic gene 18 51,419 7,913†
Mesothelin (Msln) 51,063 58,251
Tubulin, alpha 1B (Tuba1b) 50,012 63,744
ATP synthase subunit a 38,699 208,545†
Cytochrome c oxidase subunit 3 42,348 167,059†
S100 calcium-binding protein A6 (S100a6) 40,623 165,905†
Caveolin 1 (Cav1) 43,238 155,872†
Cytochrome c oxidase subunit 2 39,787 146,445†
NADH-ubiquinone oxidoreductase chain 4 34,397 128,375†
Kelch domain containing 2 (Klhdc2) 38,431 100,721†
ATP synthase F1 complex epsilon (Atp5e) 40,623 94,629†
Growth arrest specific 5 (Gas5) 42,055 93,976†
Table W4. (continued )
mRNA Mean Signal Strength*
ASMLwt Cells ASML-CD44vkd Cells
S100 calcium-binding protein A4 (S100a4) 5,405 90,148†
Serum deprivation response (Sdpr) 24,154 85,285†
Dynein heavy-10 (Dnah10) 49,667 78,478
Rap GEF 6 (Rapgef6) 48,983 77,936
NADH-ubiquinone oxidoreductase chain 2 7,750 72,717†
SMT3 suppressor of mif two 3 homolog 2 (Sumo2) 49,667 70,728
Caveolin 2 (Cav2) 23,170 68,794†
Thioredoxin 1 (Txn1) 44,453 66,913
Myosin light chain 6 (Myl6) 46,341 65,992
Translationally controlled tumor protein (TCTP) 43,538 65,536
Hepatocyte malignant transforming factor 38,431 65,083
Ubiquinol-cytochrome c reductase complex isoform b 43,841 62,866
Eukaryotic translation initiation factor 4E binding protein 1 (Eif4ebp1) 34,397 62,432
Cathepsin B (Ctsb) 36,611 60,725
Stearoyl-CoA desaturase delta (Scd) 23,494 59,064†
Parkinson protein 7 (Park7) 37,902 57,849
Glutathione peroxidase 4 (Gpx4) 46,021 57,449
Acidic (leucine-rich) nuclear phosphoprotein 32B (Anp32b) 27,175 57,449
Clathrin light chain A (Clta) 29,944 56,267
Suppressor of initiator codon mutations 33,225 54,728
Aminolevulinate dehydratase (Alad) 38,699 54,350
Protein tyrosine phosphatase F (Ptprf ) 15,076 53,602†
H1 histone family member 0 (H1f0) 5,043 53,232†
Histone cluster 1 H2ak (Hist1h2ak) 44,762 52,864
2-5 oligoadenylate synthetase 1B (Oas1b) 35,120 52,499
Eukaryotic translation initiation factor 3K (Eif3k) 48,645 50,711
Cyclin-dependent kinase inhibitor 2A (Cdkn2a) 27,746 50,711
Programmed cell death 5 (Pdcd5) 28,329 50,360
*Mean signal strength was calculated from duplicates, respectively, triplicates, after normalization (Chipster analysis and Agilent annotation) of two independently performed microarray analyses. Only
cellular mRNA with a signal strength of >50,000 is shown.
†Signal strength with a more than two-fold change between ASMLwt and ASML-CD44vkd cells.
Table W5. Distinctly Recovered mRNA in ASMLwt and ASML-CD44vkd Exosomes versus Cells.
mRNA Mean Signal Strength* ASMLwt Exosomes
versus Cells
Mean Signal Strength* ASML-CD44vkd Exosomes
versus Cells
ASMLwt ASML-CD44vkd
Exosomes Cells Exosomes Cells
Translationally controlled tumor protein 1 (Tpt1) 21,555 104,273 0.21 20,863 153,726 0.14
Ferritin 1 (Fth1) 21,061 169 124.70 18,061 131 138.20
Laminin receptor 1 (Lamr1) 19,878 nd† ∞ 20,967 nd ∞
Keratin complex 1-19 (Krt1-19) 14,348 73 197.89 13,274 79 168.47
Actin, beta (Actb) 12,963 106,464 0.12 18,280 48,645 0.38
Calmodulin 2 (Calm2) 12,033 51,776 0.23 15,726 60,725 0.26
Ornithine decarboxylase antizyme 1 (Oaz1) 11,924 90 132.67 13,427 80 166.90
Metallothionein (MT1a) 9,659 596 16.20 5,546 526 10.54
Peroxiredoxin 1 (Prdx1) 9,436 77 122.27 12,336 104 118.65
Non-metastatic cells 2 (Nme2) 9,417 nd ∞ 9,113 nd ∞
Phosphoglycerate kinase 1 (Pgk1) 9,391 89 105.21 12,013 131 91.92
Annexin A2 (Anxa2) 9,196 145,433 0.06 8,734 133,826 0.07
Synaptic vesicle glycoprotein 2b (Sv2b) 9,153 nd ∞ 3,304 nd ∞
Annexin A1 (Anxa1) 9,072 129,267 0.07 9,408 101,421 0.09
Villin 2 (Vil2) 9,071 nd ∞ 7,751 nd ∞
Diazepam binding inhibitor (Dbi) 8,840 80 109.88 10,165 78 130.81
Macrophage migration inhibitory factor (Mif ) 8,578 135 63.40 9,533 85 112.10
Galactose binding lectin, soluble 3 (Lgals3) 8,566 72 119.79 6,559 68 96.29
Peroxiredoxin 2 (Prdx2) 8,476 370 22.93 10,633 187 56.74
Cell division cycle 37 homolog (Cdc37) 8,377 405 20.71 11,208 269 41.71
S100 calcium-binding protein A6 (S100a6) 8,297 1,287 6.44 7,497 357 21.00
Brain protein I3 (Bri3) 8,064 21,028 0.38 10,520 15,936 0.66
Cofilin 1 (Cfl1) 8,043 46,988 0.17 12,817 25,709 0.50
Basic keratin complex 2-8 (Krt2-8) 8,015 nd ∞ 7,486 nd ∞
Phosphatidylethanolamine-binding protein (Pbp) 7,653 843 9.07 8,791 867 10.14
Proteasome subunit beta 1 (Psmb1) 7,626 80 95.46 8,227 68 121.61
Aldose reductase 1-B4 (Akr1b4) 7,411 4,096 1.81 8,827 2,937 3.01
Table W5. (continued )
mRNA Mean Signal Strength* ASMLwt Exosomes
versus Cells
Mean Signal Strength* ASML-CD44vkd Exosomes
versus Cells
ASMLwt ASML-CD44vkd
Exosomes Cells Exosomes Cells
Profilin 1 (Pfn1) 6,662 187 35.55 5,998 67 89.27
Heat shock protein 8 (Hspa8) 6,577 6,165 1.06 4,584 3,236 1.41
Cell division cycle 42 (Cdc42) 6,492 519 12.51 10,242 298 34.35
Glutathione peroxidase 2 (Gpx2) 6,434 1,226 5.25 4,124 1,209 3.41
Cytochrome c, somatic (Cycs) 6,401 343 18.69 8,157 910 8.96
Protein phosphatase 1-14B (Ppp1r14b) 6,280 34,397 0.18 4,807 22,227 0.22
Adaptor-related protein complex 2-sigma 1 (Ap2s1) 6,237 21,619 0.29 7,003 12,944 0.54
Transmembrane trafficking protein 21 (Tmp21) 6,161 nd ∞ 5,505 nd ∞
Proliferating cell nuclear antigen (Pcna) 5,845 21,469 0.27 7,698 11,426 0.67
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, zeta (Ywhaz)
5,843 4,012 1.46 7,178 5,293 1.36
Proteasome beta-4 (Psmb4) 5,697 5,113 1.11 6,876 1,053 6.53
Superoxide dismutase 1 (Sod1) 5,639 49,324 0.11 6,120 33,225 0.18
ATPase, H+ transporting, V0-C (Atp6v0c) 5,550 13,777 0.40 5,220 10,441 0.50
Proteolipid protein 2 (Plp2) 5,549 3,692 1.50 4,413 4,939 0.89
Non-metastatic cells 1 (Nme1) 5,487 20,453 0.27 5,242 16,845 0.31
C-terminal binding protein 1 (Ctbp1) 5,416 24,492 0.22 8,964 11,191 0.80
ARP2 actin-related 2 (Actr2) 5,387 5,914 0.91 7,636 5,480 1.39
Cytochrome c oxidase VIIb (Cox7b) 5,263 74 71.59 5,238 69 75.83
Integrin beta 4 binding protein (Itgb4bp) 5,252 8,719 0.60 4,039 27,939 0.14
Proteasome beta 2 (Psmb2) 5,169 176 29.36 5,941 74 80.81
Radixin (Rdx) 5,165 17,929 0.29 4,787 187 25.54
Cyclin D1 (Ccnd1) 5,160 4,576 1.13 8,670 1,783 4.86
Peptidylprolyl isomerase B (Ppib) 5,083 68 75.14 3,001 72 41.68
S-phase kinase-associated 1A (Skp1a) 4,916 10,369 0.47 5,992 5,914 1.01
Tubulin beta 2 (Tubb2) 4,851 609 7.97 6,840 1,160 5.90
SMT3 suppressor of mif two 3-1 (Sumo1) 4,843 7,913 0.61 7,168 8,192 0.88
Glutathione peroxidase 4 (Gpx4) 4,840 93 52.01 4,487 75 60.19
Chromobox homolog 3 (Cbx3) 4,839 1,113 4.35 5,945 798 7.45
Poly(A)-binding protein 1 (Pabpc1) 4,788 186 25.73 3,177 239 13.30
Dynein light chain 2A (Dncl2a) 4,747 2,320 2.05 3,733 1,003 3.72
Aldo-keto reductase 1-A1 (Akr1a1) 4,656 9,345 0.50 7,095 12,161 0.58
Tyrosine 3/tryptophan 5-monooxygenase ɛ (Ywhae) 4,646 31,433 0.15 9,089 33,689 0.27
MAP kinase kinase 2 (Map2k2) 4,573 30,362 0.15 4,357 26,801 0.16
S100 calcium-binding protein A4 (S100a4) 4,495 92 48.98 4,424 1,261 3.51
Dynein light chain 1 (Dnclc1) 4,444 333 13.34 3,237 508 6.37
ATX1-1 (Atox1) 4,389 13,308 0.33 3,323 6,383 0.52
Beta-2 microglobulin (B2m) 4,380 26,987 0.16 3,997 22,694 0.18
Aldolase A (Aldoa) 4,313 19,619 0.22 2,549 8,841 0.29
Lactate dehydrogenase A (Ldha) 4,278 333 12.84 3,623 498 7.28
RAN, member RAS oncogene family (Ran) 4,266 72 59.66 4,704 167 28.24
Hepatoma-derived growth factor (Hdgf) 4,232 48,309 0.09 5,068 35,364 0.14
Catenin alpha 1 (Catna1) 4,168 3,169 1.32 7,307 3,083 2.37
Complement component 1q (C1qbp) 4,158 516 8.07 4,389 2,759 1.59
Fertility protein SP22 (Park7) 4,146 nd ∞ 5,720 nd ∞
Thioredoxin 1 (Txn1) 4,141 44,453 0.09 3,567 66,913 0.05
Chaperonin subunit 4 (Cct4) 4,101 127 32.26 4,233 162 26.13
Transaldolase 1 (Taldo1) 3,997 10,441 0.38 6,234 13,308 0.47
NADH dehydrogenase 1 alpha-5 (Ndufa5) 3,923 83 47.43 4,170 73 57.12
Cytochrome c oxidase Va (Cox5a) 3,901 452 8.63 2,557 252 10.13
cAMP-regulated phosphoprotein 19 (Arpp19) 3,899 15,608 0.25 2,628 7,132 0.37
Proteasome 26S subunit 3 (Psmd3) 3,880 556 6.97 4,621 85 54.34
Cytochrome c oxidase subunit IV-1 (Cox4i1) 3,864 79 49.04 3,441 77 44.59
Amino-terminal enhancer of split (Aes) 3,864 1,287 3.00 3,421 750 4.56
Proteasome beta-3 (Psmb3) 3,860 2,610 1.48 5,159 152 33.89
Myelocytomatosis viral oncogene- (Myc) 3,854 792 4.86 3,028 508 6.00
LIM domain only 4 (Lmo4) 3,812 322 11.85 4,896 413 11.85
Cyclin-dependent kinase 4 (Cdk4) 3,807 639 5.96 4,695 942 4.98
Spastic paraplegia 21 (Spg21) 3,786 3,421 1.11 3,641 1,351 2.69
Proteasome alpha-6 (Psma6) 3,740 311 12.03 4,015 81 49.56
FK506 binding protein 1a (Fkbp1a) 3,734 91 41.26 3,195 91 35.06
Cold shock domain protein A (Csda) 3,682 107 34.45 4,488 81 55.40
Neural precursor cell expressed, developmentally
downregulated 8 (Nedd8)
3,674 4,705 0.78 2,801 9,675 0.29
Rho GDP dissociation inhibitor (GDI) alpha 3,662 202 18.11 5,106 95 53.74
Guanine nucleotide binding protein α inhibitor 2 (Gnai2) 3,635 1,846 2.00 3,602 1,399 2.57
Peroxiredoxin 5 (Prdx5) 3,602 71 51.07 3,060 71 43.09
DnaJ (Hsp40)subfamily A-2 (Dnaja2) 3,586 76 47.44 5,134 78 65.61
Spermidine/spermine N 1-acetyl transferase (Sat) 3,571 7,332 0.49 3,937 15,500 0.25
Table W5. (continued )
mRNA Mean Signal Strength* ASMLwt Exosomes
versus Cells
Mean Signal Strength* ASML-CD44vkd Exosomes
versus Cells
ASMLwt ASML-CD44vkd
Exosomes Cells Exosomes Cells
CD24 3,455 2,353 1.47 4,445 3,541 1.26
Aldo-keto reductase 1-B8 (Akr1b8) 3,432 30,153 0.11 1,313 6,794 0.19
Annexin A4 (Anxa4) 3,421 101 33.83 4,578 90 50.94
Tubulin alpha 1 (Tuba1) 3,388 28,924 0.12 5,870 14,869 0.39
Galactokinase 1 (Galk1) 3,366 91 37.19 4,419 95 46.51
ARP10 actin-related protein 10 (Actr10) 3,336 11,666 0.29 4,332 5,793 0.75
S -adenosylhomocysteine hydrolase (Ahcy) 3,328 nd ∞ 2,459 nd ∞
NADH dehydrogenase 1 alpha 11 (Ndufa11) 3,324 180 18.49 3,244 155 20.87
t-complex protein 1 (Tcp1) 3,294 25,709 0.13 3,109 21,769 0.14
Phosphoserine phosphatase (Psph) 3,287 107 30.75 3,115 94 33.01
Inosine 5-monophosphate dehydrog.2 (Impdh2) 3,261 nd ∞ 2,763 nd ∞
Chaperonin subunit 3 (Cct3) 3,249 5,753 0.56 4,492 5,955 0.75
Protein phosphatase 2a alpha (Ppp2ca) 3,218 2,402 1.34 3,835 2,353 1.63
Upregulated by 1,25-dihydroxyvitamin D-3 (Txnip) 3,214 3,492 0.92 6,130 6,039 1.02
Microtubule-associated protein light chain 1A/1B
light 3 (Map1lc3b)
3,176 1,438 2.21 6,066 449 13.51
Glucose phosphate isomerase (Gpi) 3,158 71 44.78 3,444 87 39.39
Annexin A5 (Anxa5) 3,115 5,634 0.55 2,642 3,566 0.74
Coated vesicle membrane protein (Rnp24) 3115 nd ∞ 2,593 nd ∞
Peroxiredoxin 6 (Prdx6) 3,108 74 41.98 3,706 67 55.54
GDP dissociation inhibitor 2 (Gdi2) 3,077 70 44.24 5,625 69 81.43
Cytochrome c oxidase subunit Vb (Cox5b) 3,037 83 36.46 2,219 74 30.19
MAP kinase-interacting serine/threonine
kinase 2 (Mknk2)
3,025 nd ∞ 3,221 nd ∞
*mRNA was ordered according to the signal strength in ASMLwt exosomes (mean signal strength was calculated from duplicates, respectively, triplicates, after normalization of two independently
performed microarray analyses. Only defined mRNA with a mean signal strength of >3000 was included.
†nd: below the detection limit in cell extract. There has been no ASML-CD44vkd mRNA opposing regulated in cells versus exosomes.
Figure W2. Comparison of the ratio of exosomal ASMLwt to ASML-CD44vkd mRNA with the ratio of cellular to exosomal mRNA: Scatter
blot of exosomal mRNA that differs more than two-fold between ASMLwt versus ASML-CD44vkd exosomes as well as the ratios of the
ASMLwt and ASML-CD44vkd cellular to exosomal mRNA. For abbreviations, see TablesW4 andW5. With four exceptions (ovarian failure1B,
Scfd1, Pfn2, and Clic2), signals for both ASMLwt and ASML-CD44vkd cellular mRNA are either enriched or reduced compared to the exo-
somal mRNA signal strength. This finding strongly argues against CD44v being directly engaged in mRNA recruitment into MVB.
Figure W1. Comparison of ASMLwt and ASML-CD44vkd exosomal versus cellular mRNA. (A) The 100 exosomal ASMLwt mRNAs with the
highest signal strength and, for comparison, the corresponding cellular mRNAs and (B) the 100 exosomal ASML-CD44vkd mRNAs with
the highest signal strength and, for comparison, the corresponding cellular mRNAs are shown. The mean signal strength of duplicates,
respectively, triplicates, of two independent microarray analyses is shown. For more detailed information and full names, see Table W5.
Independent of CD44v expression, the composition of exosomal and cellular mRNAs differs strongly.
Figure W3. Comparison of cellular ASMLwt and ASML-CD44vkd mRNA whose proteins are enriched in exosomes: Scatter blot of mean
cellular mRNA signal strength in ASMLwt and ASML-CD44vkd cells. Only mRNAs whose proteins are known to be enriched in exosomes are
shown, where from 164mRNAs the 100 with high signal strength have been selected. Themean signal strength of duplicates, respectively,
triplicates, of two independent microarray analyses is shown. mRNAs with a more than two-fold change in the signal strength between
ASMLwt versus ASML-CD44kd cells are indicated by larger symbols. For abbreviations, see Table W3. In comparison to the impact of CD44v
on the total cellular mRNA, CD44v rather abundantly affects mRNA, where translation products are enriched in exosomes.
Table W6. miRNA in ASMLwt and ASML-CD44vkd Exosomes and Cells.
(A) Exosomal miRNA
miRNA Mean Signal Strength* ASMLwt/ASML-CD44vkd Exosomes
ASMLwt ASML-CD44vkd
Exosomes
let-7a 2,710 2,808 0.97
let-7b 5,038 14,760 0.34†
let-7c 24,097 29,257 0.82
let-7d 1,148 377 3.04†
let-7e 12,646 32,111 0.39†
let-7f 961 971 0.99
let-7i 346 561 0.62
miR-101b 285 853 0.33†
miR-103 1,468 637 2.30†
miR-106b 1,520 2,228 0.68
miR-10a-3p 425 484 0.88
miR-10a-5p 166 445 0.37†
miR-122 236 400 0.59
miR-124 2,332 1,163 2.00†
miR-125a-3p 1,574 1,815 0.87
miR-125a-5p 9,079 2,077 4.37†
miR-125b-3p 29,549 5,541 5.33†
miR-125b-5p 2,144 1,825 1.18
miR-127 1,209 356 3.40†
miR-129 15,607 7,956 1.96
miR-130b 3,032 2,086 1.45
miR-138 1,791 3,036 0.59
miR-142-5p 541 990 0.55
miR-147 337 496 0.68
miR-148b-3p 1,924 528 3.64†
miR-150 2,415 2,151 1.12
miR-183 429 292 1.47
miR-184 5,936 7,438 0.80
miR-185 655 1,510 0.43†
miR-193 416 191 2.17†
miR-196a 293 416 0.70
miR-200b 492 339 1.45
miR-200c 697 511 1.36
miR-204 24,335 23,711 1.03
miR-206 6,513 4,944 1.32
miR-207 4,876 8,012 0.61
miR-208 686 941 0.73
miR-21 11,462 5,333 2.15†
miR-214 9,826 3,482 2.82†
miR-22 427 945 0.45†
miR-221 1,421 979 1.45
miR-222 848 909 0.93
miR-23a 692 754 0.92
miR-23b 1,401 1,120 1.25
miR-24 35,571 6,978 5.10†
miR-26b 7,022 26,350 0.27
miR-290 12,052 11,948 1.01
miR-291a-5p 5,534 627 8.83†
miR-296 33,359 9,235 3.61†
miR-298 266 454 0.59
miR-29a 1,808 911 1.99
miR-29b 1,281 676 1.90
miR-29c 1,118 533 2.10†
miR-300-3p 1,951 1,213 1.61
miR-300-5p 65,490 7,287 8.99†
miR-30b-3p 2,348 5,402 0.43†
miR-30b-5p 345 401 0.86
miR-30c 5,715 1,870 3.06†
miR-31 533 563 0.95
miR-323 1,910 964 1.98
miR-325-3p 7,129 5,608 1.27
miR-325-5p 522 1,617 0.32†
miR-327 463 392 1.18
miR-329 745 1,048 0.71
miR-330 285 1,181 0.24†
miR-331 585 4,471 0.13
miR-341 13,956 9,369 1.49
miR-342-5p 404 999 0.40†
miR-347 801 1,084 0.74
miR-34a 650 5,420 0.12†
Table W6. (continued )
(A) Exosomal miRNA
miRNA Mean Signal Strength* ASMLwt/ASML-CD44vkd Exosomes
ASMLwt ASML-CD44vkd
Exosomes
miR-34c 410 565 0.72
miR-350 245 455 0.54
miR-351 3,707 1,558 2.38†
miR-352 435 525 0.83
miR-361 777 950 0.82
miR-363 1,692 181 9.34†
miR-370 98 579 0.17†
miR-377 324 753 0.43†
miR-381 433 480 0.90
miR-382 18,070 3,630 4.98†
miR-409-5p 375 1,801 0.21†
miR-423 4,548 1,448 3.14†
miR-466c 403 674 0.60
miR-471 432 826 0.52
miR-494 31,123 14,605 2.13†
miR-500 1,225 548 2.24†
miR-503 14,520 7,329 1.98
miR-540 378 578 0.66
miR-542-3p 14,225 2,133 6.67†
miR-542-5p 463 213 2.18†
miR-551b 1,794 2,050 0.87
miR-652 436 129 3.38†
miR-664 386 592 0.65
miR-743a 247 611 0.40†
miR-743b 277 497 0.56
miR-7a 569 5,188 0.11†
miR-872 851 706 1.21
miR-874 3,096 1,075 2.88†
miR-877 4,763 4,625 1.03
miR-96 417 118 3.54†
miR-98 453 559 0.81
miR-99b 1,359 5,133 0.26†
(B) Cellular miRNA
miRNA Mean Signal Strength* ASMLwt/ASML-CD44vkd Cells
ASMLwt ASML-CD44vkd
Cells
let-7a 13,560 15,699 0.86
let-7b 7,125 10,683 0.67
let-7c 7,963 15,121 0.53
let-7d 6,440 5,844 1.10
let-7e 1,158 3,018 0.38†
let-7f 15,565 16,357 0.95
let-7i 4,485 5,129 0.87
miR-100 935 1,401 0.67
miR-101b 700 488 1.43
miR-103 2,369 2,380 1.00
miR-106b 4,409 4,475 0.99
miR-107 2,664 2,503 1.06
miR-10a-5p 5,116 6,966 0.73
miR-1224 992 566 1.75
miR-125a-5p 630 1,424 0.44†
miR-125b-5p 32,799 46,281 0.71
miR-128 491 429 1.15
miR-130a 3,199 5,535 0.58
miR-130b 1,396 1,288 1.08
miR-140 689 814 0.85
miR-141 1,744 607 2.87†
miR-148b-3p 501 466 1.08
miR-151 857 1,056 0.81
miR-15b 5,295 5,005 1.06
miR-16 10,127 9,008 1.12
miR-181c 428 708 0.60
miR-181d 453 467 0.97
miR-182 948 845 1.12
miR-183 1,854 2,431 0.76
Table W6. (continued )
(B) Cellular miRNA
miRNA Mean Signal Strength* ASMLwt/ASML-CD44vkd Cells
ASMLwt ASML-CD44vkd
Cells
miR-185 749 432 1.73
miR-186 1,606 610 2.63†
miR-193 329 498 0.66
miR-1949 2,018 614 3.29†
miR-196c 793 456 1.74
miR-200a 2,646 560 4.73†
miR-200b 4,467 949 4.71†
miR-200c 1,192 186 6.40†
miR-203 1,524 2,645 0.58
miR-207 286 523 0.55
miR-21 57,732 47,159 1.22
miR-210 747 1,056 0.71
miR-218a 307 548 0.56
miR-22 4,177 5,884 0.71
miR-221 2,233 5,340 0.42
miR-222 1,217 1,459 0.83
miR-23a 12,378 22,556 0.55
miR-23b 4,652 5,909 0.79
miR-24 6,898 13,293 0.52
miR-25 4,572 3,947 1.16
miR-26a 3,053 4,094 0.75
miR-26b 2,252 3,084 0.73
miR-27a 4,819 12,832 0.38†
miR-27b 2,823 3,969 0.71
miR-28 555 431 1.29
miR-29a 37,744 37,658 1.00
miR-29b 11,953 24,913 0.48†
miR-29c 2,719 2,862 0.95
miR-301a 469 1,559 0.30†
miR-30a 928 1,013 0.92
miR-30b-5p 1,262 1,222 1.03
miR-30c 2,404 2,207 1.09
miR-30d 492 478 1.03
miR-30e 1,160 1,407 0.82
miR-31 8,921 1,2526 0.71
miR-32 378 623 0.61
Table W6. (continued )
(B) Cellular miRNA
miRNA Mean Signal Strength* ASMLwt/ASML-CD44vkd Cells
ASMLwt ASML-CD44vkd
Cells
miR-322 614 453 1.36
miR-324-3p 971 1,041 0.93
miR-335 433 531 0.82
miR-34a 597 1,305 0.46†
miR-34b 669 355 1.89
miR-34c 720 320 2.25†
miR-361 414 436 0.95
miR-365 1,493 1,426 1.05
miR-374 539 418 1.29
miR-425 386 547 0.71
miR-429 2,625 544 4.83†
miR-466b-1 1,129 1,481 0.76
miR-466b-2 1,296 1,643 0.79
miR-466c 1,015 1,430 0.71
miR-485 312 579 0.54
miR-494 707 417 1.70
miR-500 432 457 0.95
miR-582 407 92 4.44†
miR-652 1,366 1,756 0.78
miR-672 394 1,063 0.37†
miR-741-3p 11 857 0.01†
miR-764 312 647 0.48†
miR-7a 1,850 373 4.96†
miR-872 692 748 0.92
miR-883 7 438 0.02†
miR-9 486 387 1.25
miR-93 1,936 1,727 1.12
miR-96 5,737 5,758 1.00
miR-98 1,139 1,932 0.59
miR-99a 152 4,253 0.04†
miR-99b 528 891 0.59
*All miRNAs (in alphabetic order) with a mean signal strength (quadruplicates, two independently
performed microarray analyses) after normalization (Chipster analysis and Agilent annotation by Agi-
lent Feature Extraction software) of >400 in ASMLwt or ASML-CD44vkd exosomes or cells are shown.
†miRNA that differs between ASMLwt versus ASML-CD44vkd exosomes or cells in signal intensity
by more than two-fold.
Figure W4. Comparative analysis of ASMLwt and ASML-CD44vkd cellular and exosomal miRNAs. (A–D) Presentation of the most abun-
dant miRNA in ASMLwt and, for comparison, in ASML-CD44vkd cells and exosomes. The mean signal strength of quadruplicates of two
independent microarray analyses is shown. ASML exosomes and cells contain a limited number of miRNA that differ significantly be-
tween cells and exosomes and in dependence on CD44v expression.
Figure W5. Comparison of miRNA in ASMLwt versus ASML-CD44vkd cells and exosomes. (A) Cellular and (B) exosomal miRNAs with a
signal strength > 1000 and a more than two-fold difference in signal strength in ASMLwt versus ASML-CD44vkd cells or exosomes (mean
signal strength of quadruplicates of two independent microarray analyses) is shown; Opposingly regulated miRNA in cells versus exo-
somes are indicated by X and alike regulated miRNA by asterisk. Independent of CD44v expression, most abundantly recovered cellular
and exosomal miRNAs differ significantly, confirming the selectivity of miRNA recruitment.
Figure W6. Exosome transfer–promoted activities of target cells in the premetastatic niche. Exosome uptake–induced upregulated
mRNAs in LnStr were grouped according to main functional activities and are presented according to the fold up-regulation. Short
comments on the main activity of upregulated genes and related references are given below.
Matrix modulation
MMP3 (matrix metallopeptidase 3): matrix degradation, well organized role in invasion and metastasis
Hua H, Li M, Luo T, Yin Y, and Jiang Y (2011). Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci
68, 3853–3868.
PRG4 (proteoglycan 4): co-receptor for integrins, co-operates with MT1-MMP in collagen modulation.
Vuoriluoto K, Högnäs G, Meller P, Lehti K, and Ivaska J (2011). Syndecan-1 and -4 differentially regulate oncogenic K-ras dependent cell
invasion into collagen through α2β1 integrin and MT1-MMP. Matrix Biol 30, 207–217.
SLPI (secretory leukocyte peptidase inhibitor): often upregulated in cancer, induces MMP9 transcription.
Nukiwa T, Suzuki T, Fukuhara T, and Kikuchi T (2008). Secretory leukocyte peptidase inhibitor and lung cancer. Cancer Sci 99, 849–855.
Hoskins E, Rodriguez-Canales J, Hewitt SM, Elmasri W, Han J, Han S, Davidson B, and Kohn EC (2011). Paracrine SLPI secretion
upregulates MMP-9 transcription and secretion in ovarian cancer cells. Gynecol Oncol 122, 656–662.
ADAMTS1 (a disintegrin-like and metalloprotease with thrombospondin type 1, motif 1); ADAMTS8 (a disintegrin-like and metalloprotease
with thrombospondin type 1, motif 8); ADAMTS5 (a disintegrin-like and metalloprotease with thrombospondin type 1, motif 5): procollagen
maturation, extracellular matrix proteolysis related to angiogenesis and metastasis.
Apte SS (2009). A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily:
functions and mechanisms. J Biol Chem 284, 31493–31497.
Adhesion/motility
CXCL2 (C-X-C chemokine ligand 2), CCL20 (C-C chemokine ligand 20), CCL19 (C-C chemokine ligand 19), CXCL1 (CXC chemokine ligand 1):
chemokines and their ligands largely determine organ specificity of metastases, facilitating migration and extravasation; they can be involved
in tumor cell proliferation and survival.
Ben-Baruch A (2008). Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 25, 345–356.
VCAM1 (vascular cell adhesion molecule 1); ICAM1 (intercellular adhesion molecule 1): metastasis promoting by engagement in migration,
proliferation, angiogenesis, and thrombosis.
Mousa SA (2008). Cell adhesion molecules: potential therapeutic & diagnostic implications. Mol Biotechnol 38, 33–40.
MGP (matrix Gla protein): migration promoting, overexpressed in cancer.
Mertsch S, Schurgers LJ, Weber K, Paulus W, and Senner V (2009). Matrix gla protein (MGP): an overexpressed and migration-
promoting mesenchymal component in glioblastoma. BMC Cancer 9, 302.
CD49a (integrin alpha 1): supports tumor cell migration.
Madsen CD and Sahai E (2010). Cancer dissemination—lessons from leukocytes. Dev Cell 19, 13–26.
Angiogenesis
PTGS2/COX2 (prostaglandin-endoperoxide synthase 2): involved in inflammation, increased in more aggressive forms of colorectal
cancer, known to promote angiogenesis.
Wang S, Liu Z, Wang L, and Zhang X (2009). NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol
6, 327–334.
RGS2 (regulator of G-protein signaling 2): critical regulator of proangiogenic function of MDSC.
Boelte KC, Gordy LE, Joyce S, Thompson MA, Yang L, and Lin PC (2011). Rgs2 mediates pro-angiogenic function of myeloid derived
suppressor cells in the tumor microenvironment via upregulation of MCP-1. PLoS One 6, e18534.
ANKRD1 (ankyrin repeat domain 1): co-transcription factor involved in angiogenesis.
Samaras SE, Shi Y, and Davidson JM (2006). CARP: fishing for novel mechanisms of neovascularization. J Investig Dermatol Symp Proc
11, 124–131.
Oxidative stress
MT1a (metallothionein): contributes to protective reactions with chemotherapeutic agents that are electrophiles or can generate reactive
oxygen species.
Namdarghanbari M, Wobig W, Krezoski S, Tabatabai NM, and Petering DH (2011). Mammalian metallothionein in toxicology, cancer, and
cancer chemotherapy. J Biol Inorg Chem 16, 1087–1101.
Haptoglobin: CD163 clearance and metabolism of “free” hemoglobin released during intravascular hemolysis. This scavenging system
counteracts the potentially harmful oxidative and NO-scavenging effects associated with “free” hemoglobin.
Nielsen MJ and Moestrup SK (2009). Receptor targeting of hemoglobin mediated by the haptoglobins: roles beyond heme scavenging.
Blood 114, 764–771.
SOD2 (superoxide dismutase 2): catalysis oxidative stress, upregulated in metastasis.
Hempel N, Carrico PM, and Melendez JA (2011). Manganese superoxide dismutase (Sod2) and redox-control of signaling events that drive
metastasis. Anticancer Agents Med Chem 11, 191–201.
AMACR (α-methylacyl-CoA racemase): catalyzes the chiral inversion of a diverse number of 2-methyl acids (as their CoA esters) and regu-
lates the entry of branched-chain lipids into the peroxisomal and mitochondrial β-oxidation pathways; linked with prostate, breast, colon,
and other cancers.
Lloyd MD, Darley DJ, Wierzbicki AS, and Threadgill MD (2008). Alpha-methylacyl-CoA racemase—an ‘obscure’ metabolic enzyme takes
centre stage. FEBS J 275, 1089–1102.
FST (follistatin): Localization of FST to the nucleolus attenuates rRNA synthesis, a key process for cellular energy homeostasis and cell
survival. Overexpression of FST delays glucose deprivation–induced apoptosis and promotes survival.
Gao X, Wei S, Lai K, Sheng J, Su J, Zhu J, Dong H, Hu H, and Xu Z (2010). Nucleolar follistatin promotes cancer cell survival under glucose-
deprived conditions through inhibiting cellular rRNA synthesis. J Biol Chem 285, 36857–36864.
MDR1 (ATP-binding cassette, subfamily B, member 1): promotes drug resistance, high expression frequently associatedwithmetastasizing
cancer-initiating cells.
Adhikari AS, Agarwal N, and Iwakuma T (2011). Metastatic potential of tumor-initiating cells in solid tumors. Front Biosci 16, 1927–1938.
Proliferation
PLA2g2A (phospholipase A2, group 2A): contributes to EGFR activation.
HernándezM, Martín R, García-Cubillas MD, Maeso-Hernández P, and Nieto ML (2010). Secreted PLA2 induces proliferation in astrocytoma
through the EGF receptor: another inflammation-cancer link. Neuro Oncol 12, 1014–1023.
RASL11b (RAS-like family 11 member B): RasL11b acts in concert with UBF to facilitate initiation and/or elongation by RNA polymerase II,
suggested to be upregulated in cancer.
Stolle K, Schnoor M, Fuellen G, Spitzer M, Cullen P, and Lorkowski S (2010). Cloning, genomic organization, and tissue-specific expression
of the RASL11B gene. Biochim Biophys Acta 1769, 514–524.
Pistoni M, Verrecchia A, Doni M, Guccione E, and Amati B (2010). Chromatin association and regulation of rDNA transcription by the
Ras-family protein RasL11a. EMBO J 29, 1215–1224.
SSB1 (similar to SPRY domain-containing SOCS box protein): binds to MET and enhances the HGF-induced Erk–Elk-1–SRE pathway.
Wang D, Li Z, Messing EM, and Wu G (2005). The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET and enhances
the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway. J Biol Chem 280, 16393–16401.
AFP (alpha-fetoprotein): tumor growth enhancing, possesses proangiogenic properties.
Mizejewski GJ (2007). Physiology of alpha-fetoprotein as a biomarker for perinatal distress: relevance to adverse pregnancy outcome.
Exp Biol Med 232, 993–1004.
Not settled
MYH11 (myosin heavy chain 11): not settled, known to fuse with CBF in leukemia.
Weckerle AB, Santra M, Ng MC, Koty PP, and Wang YH (2011). CBFB andMYH11 in inv(16)(p13q22) of acute myeloid leukemia displaying
close spatial proximity in interphase nuclei of human hematopoietic stem cells. Genes Chromosomes Cancer 50, 746–755.
EDN1 (endothelin 1): not settled, peptide hormone signaling through its cognate receptor, the endothelin-A receptor, critical for patterning,
relation to cancer unknown.
Clouthier DE, Garcia E, and Schilling TF (2010). Regulation of facial morphogenesis by endothelin signaling: insights from mice and fish.
Am J Med Genet A 152A, 2962–2973.
α2M (alpha-2-macroglobulin): interacts and captures virtually any proteinase.
Woessner JF Jr (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5, 2145–2154.
SLC40a1 (solute carrier family 39 iron-regulated transporter, member 1): iron export, may inhibit metastasis.
Jiang XP, Elliott RL, and Head JF (2010). Manipulation of iron transporter genes results in the suppression of human and mouse mammary
adenocarcinomas. Anticancer Res 30, 759–765.
SCGB1A1 (secretoglobin, family 1A, member 1): downstream target for a homeodomain transcription factor NKX2-1, which is critical for
the development of lung, thyroid, and ventral forebrain, upregulated in lung cancer.
Kurotani R, Kumaki N, Naizhen X, Ward JM, Linnoila RI, and Kimura S (2011). Secretoglobin 3A2/uteroglobin-related protein 1 is a novel
marker for pulmonary carcinoma in mice and humans. Lung Cancer 71, 42–48.
PPP1R3C (protein phosphatase 1, regulatory (inhibitor) subunit 3C): correlates with glycogen accumulation under hypoxia, described as a
candidate tumor suppressor.
Shen GM, Zhang FL, Liu XL, and Zhang JW (2010). Hypoxia-inducible factor 1-mediated regulation of PPP1R3C promotes glycogen accu-
mulation in human MCF-7 cells under hypoxia. FEBS Lett 584, 4366–4372.
Bonazzi VF, Irwin D, and Hayward NK (2009). Identification of candidate tumor suppressor genes inactivated by promoter methylation
in melanoma. Genes Chromosomes Cancer 48, 10–21.
Metastasis opposing
Properdin: antiangiogenic.
Kemper C, Atkinson JP, and Hourcade DE (2010). Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol
28, 131–155.
GADD45g (growth arrest and DNA-damage-inducible 45γ): supposed to function as metastasis inhibitor.
Ying J, Srivastava G, Hsieh WS, Gao Z, Murray P, Liao SK, Ambinder R, and Tao Q (2005). The stress-responsive gene GADD45G is
a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin
Cancer Res 11, 6442–6449.
BTG2 (B-cell translocation gene 2): antiproliferative, pan cell cycle modulator and endogenous cell death molecule, downregulated
in cancer.
Lim IK (2006). TIS21 (/BTG2/PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule. J Cancer
Res Clin Oncol 132, 417–426.
FABP3 (fatty acid binding protein 3): inhibits proliferation and promotes apoptosis
Zhu C, Hu DL, Liu YQ, Zhang QJ, Chen FK, Kong XQ, Cao KJ, Zhang JS, and Qian LM (2011). Fabp3 inhibits proliferation and promotes
apoptosis of embryonic myocardial cells. Cell Biochem Biophys 60, 259–266.
Figure W7. A metastasis-associated gene, its impact on exosome shaping, and the impact on host cells: (A) CD44v6 influences gene
transcription and posttranscription modulation. This influences the protein [1,2], mRNA, and miRNA composition of exosomes. Exo-
somes reach premetastatic organs from a distantly located primary tumor (demonstrated for draining lymph nodes, accounts equally
for other metastatic organs and the bone marrow, as well as for transfer through the blood [2,3]). (B) Exosomes bind selected target
cells (demonstrated for LnStr and LuFb, additional preferred targets for ASML exosomes are monocytes/monocyte progenitors [3]).
(C) Exosome binding is supposed to initiate signal transduction in target cells [4] (not approached in the present manuscript) and
severely affect the host matrix (unpublished). (D) Exosomes are taken up and uptaken mRNA and miRNA are recovered in the target
cell. According to our findings, uptaken miRNA severely modulates the target cell, fitting the demands for premetastatic niche formation
(only demonstrated for metastatic organ stroma cells but accounts equally well for hematopoietic cells).
Taken that tumor exosomes are recovered in patients’ sera [5] and exhibit very selective binding implies that functional activity of
exosomes has to be taken into account at sites distant from the tumor (e.g., premetastatic organs), where the selectivity of exosome
uptake will greatly facilitate therapeutic interference. However and notably, as the exosome composition becomes significantly
influenced also by proteins of the tumor cell that are not engaged in exosome assembly or transport, it is essential to characterize
the individual patient’s exosomes in advance, which can be approached by tumor exosomes in the patient’s serum.
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